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ABSTRACT 
 
Despite being a fulminant pathogen, Neisseria meningitidis (meningococcus) is 
part of the commensal flora of the human nasopharynx. Globally, five 
meningococcal serogroups (A, B, C, Y and W135) cause the majority of invasive 
disease. Most serogroup B cases occur sporadically but may be endemic or 
epidemic within a geographic region. In South Africa, there are limited data on 
invasive serogroup B clones and the antigenic diversity of certain meningococcal 
outer membrane proteins. This study examined the molecular epidemiology of 
serogroup B meningococci in South Africa from 2002 through 2006. 
 
Invasive meningococcal isolates were submitted to a national laboratory-based 
surveillance system. For this study, serogroup B isolates were characterised by 
pulsed-field gel electrophoresis (PFGE), PorA, FetA and multilocus sequence 
(MLST) typing. PorA, FetA and multilocus sequence (MLST) typing were 
performed on all 2005 isolates (n=58) and randomly selected isolates from other 
years (n=25).  
 
A total of 2144 invasive cases were reported over the study period. Of these, 76% 
(1627/2144) had viable isolates available for serogrouping and 307 (19%) were 
serogroup B. Serogroup B cases were reported from across the country however 
   
 viii 
the majority were from the Western Cape province. The highest incidence of 
serogroup B was in children less than 5 years of age.  
 
Isolates displayed a high level of diversity by PFGE. Despite this diversity the 
majority of serogroup B meningococci collected over the 5-year period could be 
grouped into several clonal clusters representative of global invasive MLST 
clonal complexes. Overall, the most predominant MLST clones in South Africa 
were ST-32/ET-5 and ST-41/44/lineage 3. In addition, at least 19 PorA types and 
16 FetA types were determined among selected isolates.  
 
Globally invasive serogroup B disease is caused by heterogeneous strains 
however, prolonged outbreaks in several countries have been due to strains of 
the ST-32/ET-5 and ST-41/44/lineage 3 clonal complexes. At present, serogroup 
B disease in South Africa is not dominated by an epidemic clone, however, global 
clonal complexes ST-32/ET-5 and ST-41/44/lineage 3 are circulating in Western 
Cape and Gauteng, respectively.  
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1 LITERATURE REVIEW 
 
Meningoccocal disease causes substantial morbidity and mortality, and despite 
treatment with antibiotics approximately 10% of cases are fatal. Among those 
who survive, 11% to 19% suffer long-term sequelae such as hearing loss, 
neurological disabilities, loss of a limb or paralysis [1;2]. Although the disease 
affects all age groups, children less than 5 years of age are most at risk [3]. 
Despite being a fulminant pathogen, Neisseria meningitidis (meningococcus) is 
part of the normal commensal flora of the human nasopharynx and, outside of 
epidemics, is carried by ∼10% of the human population [4]. 
 
1.1 The bacterium -  Neisseria meningitidis 
 
Although the disease was first described in Geneva, Switzerland in 1805, it was 
decades later in 1887 that the causative organism was discovered in Vienna by 
Anton Weichselbaum, an Austrian pathologist. Weichselbaum was able to 
isolate the organism from meningeal exudates of six cases of cerebrospinal 
fever. He called the bacterium Diplococcus intracellular meningitidis, which was 
later changed to Neisseria meningitidis after the German scientist Albert Neisser 
[2;5]. 
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1.1.1 Microbiologic characteristics  
N. meningitidis belongs to the genus Neisseria [6]. Other members of the genus 
include the pathogenic N. gonorrhoeae as well as the common commensal 
N. lactamica. The bacterium is a Gram-negative, aerobic diplococcus. Cocci occur 
in pairs and have a characteristic bean shape (Figure 1.1).  Meningococci require 
enriched media for growth. Blood-enriched media incubated at 35°C to 37°C in 
a moist atmosphere with 5% CO2 supports the fastidious growth of this 
organism. Colonies are convex and appear a translucent grey. 
 
 
Figure 1.1 Gram stain of cerebrospinal fluid (CSF) with Neisseria meningitidis. 
(Magnification x100, oil immersion objective) 
 
1.1.2 The polysaccharide capsule 
Meningococci may be encapsulated or unencapsulated (Figure 1.2). The cell 
produces a polysaccharide capsule that envelops the cell and serves as a major 
virulence factor [7]. It protects the underlying outer membrane, membrane 
proteins and enzymes from host defense mechanisms during transmission and 
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invasion. The capsule and certain outer membrane components have been 
studied extensively for vaccine development and are the basis for a 
classification system.  
 
 
Figure 1.2 Schematic of outer membrane components of encapsulated 
meningococci [8]. 
 
1.1.3 Classification 
Meningococcal isolates may be classified into serogroups, serotypes and 
serosubtypes [9]. Initial classification was done using serological methods and 
was based on reactivity with immunological reagents (monoclonal antibodies).  
 
Serogrouping is based on structural differences of the polysaccharide capsule 
[10]. Thirteen different serogroups have been described, ie. A, B, C, D, H, I, K, L, 
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W135, X, Y, Z and 29E, however, serogroups A, B, C, Y, W135 and X are 
responsible for virtually all cases of invasive disease. Further classification of 
meningococci into serotypes and serosubtypes are based on the antigenic 
differences of essential outer membrane proteins (OMPs) [11]. PorB (a class 2 or 
3 OMP) and PorA (a class 1 OMP), which function as porins, determine 
serotype and serosubtype, respectively. More recently FetA, an iron-regulated 
OMP has been included in routine classification [12]. Another classification 
system is immunotyping. This system classifies strains into lipooligosaccharide 
(LOS, also known as endotoxin) types L1 to L12 based on variations in the 
oligosaccharide side-chain [5;13]. Immunotypes L1 through L8 are associated 
with serogroups B and C.  
 
Classification systems have greatly improved by the replacement of serological 
methods with molecular techniques – targeting the nucleotide sequence rather 
than the protein itself. However, for immediate results serogrouping kits with 
monoclonal or polyclonal antisera are still used. While each laboratory will 
choose a classification system that suits their purpose, classification targets and 
a standardised nomenclature has been proposed by Jolley et al. 2007 [12].  The 
current scheme is as follows : 
Serogroup    : PorA type  :  FetA type :  Sequence type (clonal complex) 
E.g.  B        :  P1.19,15     :       F5-1      :       ST33 (ST-32/ET-5) 
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1.2 Carriage 
 
The human nasopharnyx is the only known reservoir for the meningococcus 
and ~10% of a population may be carriers at any given time [14;15].  The 
carriage state is asymptomatic and influenced by various host-environmental 
factors.  
 
Meningococci are transmitted via airborne droplets of salivary and mucosal 
secretions (Figure 1.3). Close contact is important for transmission as the 
bacterium is susceptible to drying [4;16]. Once acquired, the bacteria colonises 
the nasopharyngeal mucosa leading to carriage. The duration of carriage varies 
with individuals, it may be brief, days or weeks or last several months. Shortly 
after carriage the bacteria may cross the epithelial barrier and invade the 
bloodstream resulting in invasive disease. Since disease incidence is rare 
relative to carriage rates it is suggested that transmission and carriage, rather 
than invasive disease, is important for the life cycle of the meningococcus. 
 
Several characteristics and risk factors have been associated with the frequency 
of carriage [17;18]. Carriage rates are low in children under 5 years of age, peak 
in adolescents and young adults and decline with increasing age. There are 
more male than female carriers. Close contact at schools, universities, social 
gatherings, as well as over-crowded conditions are major factors for the 
increase of transmission and carriage. Social behavior such as smoking, kissing 
and attendance of pubs and clubs also increase the risk of carriage. Carried 
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meningococci are far more genetically diverse than disease-causing isolates [17]. 
In addition, almost 50% of carried isolates may lack a capsule which may 
facilitate colonisation. Although high rates of carriage have not been directly 
linked to invasive disease, asymptomatic carriers are the source of transmission 
and spread of the bacterium. 
 
 
Figure 1.3 The meningococcal transmission cycle. 
 
 
 
1.3 Disease epidemiology 
 
Although meningococcal disease occurs all over the world, there are 
geographical differences in incidence and distribution of the serogroups that 
cause disease [19;20]. Globally, serogroups A, B and C are the most common 
causes of meningococcal disease (Figure 1.4). 
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Figure 1.4 Global distribution of meningococcal serogroups causing invasive 
disease (Adapted from [21]). 
 
1.3.1 The meningitis belt 
Globally, the highest incidence of meningococcal meningitis occurs in the 
meningitis belt (Figure 1.5), a region of savannah within sub-Saharan Africa 
that extends from Senegal in the west to Ethiopia in the east. Since its estimated 
arrival on the African continent in the mid 19th century, the meningococcus has 
caused over 100 years of epidemic meningococcal disease within the meningitis 
belt [22].  
 
 
               ,C 
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Large epidemic waves occur every 5 to 12 years and last for several years 
[23;24]. Annual rates of disease follow a seasonal cycle, peaking in the dry 
season (December–May) and disappearing with the onset of the rainy season. 
Endemic conditions in sub-Saharan Africa are often considered epidemic 
elsewhere in the world.  
 
From 1970 through 1992 there was an estimated 800 000 meningococcal cases 
[3]. During a severe epidemic from 1996 to 1997, which affected Burkino Faso, 
Mali, Niger and Nigeria, approximately 190 000 cases were reported from 
January through October 1996. During this epidemic almost 20 000 cases were 
fatal.  The cause of these mass epidemics was serogroup A. While serogroups 
A, C, W135 and X are also responsible for endemic and epidemic cases within 
the meningitis belt [22;25], serogroup A predominates. 
 
1.3.2 Serogroup distribution  
Serogroup A 
Serogroup A is known to cause large epidemics [26]. Global spread of invasive 
serogroup A clones occurred over a 20 year period from the 1960s to 1980s, 
resulting in outbreaks in a number of countries, including South Africa [27]. 
Serogroup A disease is endemic in developing countries of Africa and Asia 
[10;28]. Although serogroup A has not been common in developed countries 
there has been a recent increase in invasive cases in countries such as the United 
Kingdom, Greece and Canada [29-31]. 
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  Figure 1.5 The sub-Saharan African meningitis belt [32]. 
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Serogroup C 
Serogroup C is associated with sporadic cases and is mostly endemic in 
developed countries [33-35], however small-scale outbreaks have occurred 
world wide [36]. The introduction of meningococcal serogroup C vaccines in 
parts of Europe, Canada and North and South America America has lead to 
significant decreases in serogroup C disease [21;37].  
 
Serogroup W135 
Endemic cases of serogroup W135 have been documented in the meningitis belt 
(section 1.3.1) and in countries such as Brazil [38] and Sweden [39]. The largest 
outbreaks occurred in Saudi Arabia during the Hajj pilgrimage in 2000 [40] and 
in Burkino Faso in 2001 [41]. As Hajj pilgrims travelled home to different 
continents, the outbreak clones spread globally [42]. 
 
Serogroup Y 
Serogroup Y prevalence is low and scattered across the globe. In Europe, 
serogroup Y is responsible for a small percentage of cases [43]. A case report 
from London of unusual clinical presentations associated with serogroup Y 
disease, suggested that the organism may be capsule switching from serogroup 
C to Y to evade vaccine induced immunity against serogroup C [44]. The USA 
and Canada have experienced an increase in serogroup Y cases since the early 
1990s [45-47]. 
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Serogroup X 
While the majority of invasive cases worldwide are caused by serogroups A, B, 
C, Y and W135, serogroup X has emerged as an important invasive serogroup 
in recent years [48]. Serogroup X has been identified in Europe, North America 
and Australia, while outbreaks have occurred in Africa [49-51]. 
 
Serogroup B 
Serogroup B is the main cause of meningococcal disease in industrialised and 
developing countries contributing to at least 30-80% of disease in the United 
States [52], the Netherlands [53], Europe [37], and Australia [54]. In contrast, 
serogroup B does not cause disease in the meningitis belt [3;23], the reason for 
this is still unknown.  
 
The United States conducts meningococcal disease surveillance through an 
active, population- and laboratory-based surveillance system [52;55]. Serogroup 
B accounted for approximately 32% of endemic disease (http://www.cdc.gov/ 
abcs/survreports/meningo08.pdf) in 2008. When comparing the surveillance 
report from 2007 and 2008, an increase in serogroup B incidence from 2007 to 
2008 was noted. In Europe, two networks, EU-MenNet and EU-IBIS, have 
contributed to meningococcal surveillance from 1999 to 2006 [21;37;56]. Since 
2007, surveillance has been conducted by the European Centre for Disease 
Prevention and Control. The majority of cases were caused by serogroup B and 
C. 
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Meningococcal disease prevalence in Brazil has been reported from individual 
states [38;57;58]. Sao Paulo, a large metropolitan state, documented an increase 
in serogroup B disease during the 1980s. The southern most state of Brazil, Rio 
Grande do Sul, reported an overall decrease in serogroup B disease between 
2003 and 2005. Approximately 60% of available meningococcal isolates were 
nevertheless serogroup B.  
 
Worldwide, serogroup B disease occurs  mostly as  sporadic cases but is  
endemic to many regions [2;38;59-61]. Prolonged outbreaks have occurred in 
Brazil [57], Chile [62], Cuba [63] and Oregon [64]. Serogroup B epidemics can 
span several years, as in the case of New Zealand [65], Norway [66] and the 
Netherlands [53;59]. 
 
1.3.3 South Africa 
 
“Epidemic cerebrospinal meningitis, cerebrospinal fever or ‘spotted fever’, is a 
specific disease due to the meningococcus, and should not be confused with 
meningitis of other bacteriological etiology.” 
       Dr. David Ordmen, SAMJ, 1932 [67] 
 
Meningitis was made a notifiable condition in South Africa in 1920 but the 
condition, was documented as early as 1905 in the Johannesburg Municipality 
[67]. The South African mining sector contributed a great deal to the description 
and documentation of disease characteristics [68-70]. Meningococcal outbreaks 
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were common in mines due to the crowded living and working conditions. The 
constant influx of new labourers meant the introduction of susceptible 
individuals as well as new, possibly invasive strains, into the mining 
community. Epidemiological descriptions of age, race and geographical 
distribution were based only on notifications. According to Ordmen [67], the 
meningococcus was the etiological agent responsible for the majority of 
meningitis cases amongst the miners. 
 
In 1979, serogroups A, B, C and D were reported from the Western Cape 
Province [71;72]. At that time serogrouping was not routinely done. The city of 
Cape Town was experiencing a meningococcal outbreak and therefore isolates 
from the Western Cape from 1977 through August 1979 (n=76), were further 
characterised and serogroup B accounted for 57% (43/76).  
 
By the mid 1980s serogroup B had established itself as the dominant serogroup 
in the country [73]. A 2-year retrospective study of bacterial meningitis in 
Johannesburg, from May 1980 through May 1982 described serogroups A and B 
as the cause of the majority of meningococcal cases [74]. The South African 
Department of Health continued to monitor and report on meningococcal 
disease, and although serogroup was not routinely reported [75;76], when 
determined, serogroup B was predominant in the Western Cape [77;78]. A 
meningococcal outbreak occurred in Johannesburg in 1996 [27] and the isolates 
were serogrouped (n=111). Although serogroup A (n=77) caused the outbreak, 
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serogroups B (n=18), C (n=1), Y (n=11) and W135 (n=3) were also responsible 
for some cases.  
 
Serogroup B caused 41% (251/615) of meningococcal cases in the country 
during the period 1999 to 2002 [79]. The predominance of serogroup B in the 
Western Cape and serogroup A in Gauteng was also noted for this period. Since 
1999, routine surveillance of meningococcal disease has been conducted 
through an active, national, laboratory-based surveillance system 
(http://www.nicd.ac.za /units/germs). South Africa is unique because, unlike 
many other countries where only one or two serogroups dominate, five 
serogroups (A, B, C, Y and W135) are responsible for causing disease [79-82]. In 
2003, a shift in the dominant serogroup from A to W135 in Gauteng was noted. 
Currently, serogroups B and W135 cause the majority of cases in South Africa 
[83]. Serogroup B still dominates in the Western Cape and serogroup W153 in 
Gauteng.  
 
1.4 Pathogenesis 
 
Following acquisition, meningococci may colonise the nasopharnyx which can 
result in asymptomatic carriage [2;84]. Invasive disease occurs when the 
bacterium crosses the nasopharyngeal mucosa and enters the systemic 
circulation (Figure 1.6). The disease progresses quickly as the bacterium is able 
to proliferate rapidly in the bloodstream and disseminate through the body, 
producing various symptoms as it reaches different organs. From the 
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bloodstream the meningococcus is able to cross the blood-brain barrier into the 
cerebrospinal fluid (CSF). Bacteria multiply in the CSF, which fills the 
subarachnoid space around the brain and spinal cord, causing inflammation of 
the leptomeninges [84;85]. Meningitis, septicaemia and meningitis with 
septicaemia are the most common presentations of meningococcal disease 
[1;10]. Other clinical signs and symptoms occur in varying combinations which 
may be similar to more common but less serious illnesses thus making 
diagnosis of meningococcal disease difficult. These symptoms include 
headache, fever, neck stiffness, altered mental status, non-blanching petechial 
or purpuric rash [1;2;10;86;87], vomiting, abdominal pain, lethargy, myalgia 
[1;84], pneumonia [2;84] and haemorrhagic skin lesions [88]. 
 
 Diagnosis 
Laboratory diagnosis requires specimens from normally sterile (CSF, blood, 
pleural fluid) or other infected sites [2;10;89]. Gram staining of sediment from 
blood and CSF as well as commercial latex agglutination kits (CSF and blood 
specimens only) can be used for rapid identification and serogroup results. 
Specimens are cultured but may or may not yield growth of meningococci due 
to antibiotic treatment prior to specimen taking. PCR has become an important 
diagnostic tool especially in the case of culture-negative specimens. 
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Figure 1.6 Colonisation of the nasopharyngeal mucosa by N. meningitidis and 
passage into the blood stream and cerebrospinal fluid [2]. 
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1.5 Treatment and Prevention 
 
Recovery from invasive disease requires the prompt administration of 
antibiotics which stop the proliferation of meningococci [2;10;89]. Since 
laboratory confirmation of meningococcal disease may take hours or days, 
antibiotic treatment is commenced following clinical suspicion of the disease. 
Penicillin, third-generation cephalosporins (ceftriaxone and cefotaxime) and 
chloramphenicol are effective in treatment of invasive disease. The South 
African National Department of Health Guidelines for the management, 
prevention and control of meningococcal disease in South Africa recommends 
ceftriaxone or cefotaxime as drugs of choice in suspected cases of bacterial 
meningitis [90]. 
 
Chemoprophylaxis for close contacts 
In order to prevent secondary cases antibiotic prophylaxis must be given to 
close contacts at least 24 hours after the case has been identified [91]. Hence the 
importance of a prompt and accurate laboratory diagnosis. However careful 
consideration must be given as to who falls into the category of close contact 
[91] as mass chemoprophylaxis is not recommended. Rifampicin, ceftriaxone, 
azithromycin and ciprofloxacin are effective against eradicating 
nasopharyngeal carriage, therefore preventing potential invasion or ongoing 
transmission [2;10;20]. 
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Antibiotic resistance  
Decreased susceptibility to the above recommended antibiotics has been  
reported [92]. Reports include rifampicin resistance in Israel [93] and the United 
Kingdom [94], intermediate resistance to penicillin in South Africa [80] and 
Portugal [95], and ciprofloxacin resistance in India [96] and the United States 
[97]. Despite these reports, antibiotic resistance in meningococci is not 
widespread. However prevention by vaccine immunisation may be the best 
control strategy. 
 
1.5.1 Vaccines 
 
Vaccines against the major serogroups (A, C, Y, and W135) causing 
meningococcal disease have been available since the 1970s [20;98]. The 
polysaccharide capsule serves as the antigen for these vaccines. Individual 
formulations against serogroups A and C were developed first, followed by a 
tetravalent formulation containing antigens against serogroups A, C, Y and 
W135. The tetravalent polysaccharide vaccine has been safe and immunogenic 
but has limitations. Firstly, polysaccharides are T-cell-independent antigens that 
do not need T-cell help to induce an immune response which results in poor 
immunologic memory. Secondly, polysaccharide vaccines lack immunogenicity 
in children less than 2 years of age [89;98]. These limitations encouraged the 
development of meningococcal polysaccharide-conjugate vaccines in which the 
polysaccharide is conjugated to a protein [99]. Thus the advantages of the 
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meningococcal conjugate vaccines include a T-cell-dependent immune response 
resulting in lasting immunity and efficacy in children less than 2 years of age.  
 
The success of meningocoocal serogroup C conjugate vaccine (MCC) has been 
demonstrated in the UK, which was the first country to implement the vaccine 
in November 1999 [100-102]. Other European countries soon followed. There 
was a reduction in invasive serogroup C disease as well as serogroup C 
carriage.  The successes of MCC lead to the development of a serogroup A 
conjugate vaccine (MenAfriVacTM) for Africa through the Meningitis Vaccine 
Project [103]. A tetravalent conjugate vaccine is also available, targeting 
serogroups A, C, Y and W135. This tetravalent formulation was implemented 
into the USA  immunisation schedule in 2005 [104] while in  Canada it has been 
approved for use in high risk groups [105].  
 
1.5.2 Serogroup B 
 
The serogroup B capsule 
 
The serogroup B capsule is a homopolymer of α-2,8 linked sialic acid (N-
acetylneuraminic acid) [106]. In comparison to capsules of serogroups A, C, Y 
and W135, serogroup B is unique in that it is structurally similar to human 
brain tissue [107], a characteristic it shares with the neonatal pathogen 
Escherichia coli serotype K1. Fetal brain tissue contains significant amounts of 
glycopeptides with N-acetylneuraminic acid residues bound by α-2,8 linkages. 
These glycopeptides are present in smaller amounts in adult brain tissue. 
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Thus the serogroup B capsule is poorly immunogenic in humans and cannot be 
used as a vaccine antigen. Efforts to increase immunogenicity by manipulating 
the polysaccharide structure, conjugation of polysaccharide to a protein carrier 
(e.g. tetanus toxoid) and selective use of adjuvants have given good results 
[107;108]. However there are concerns of inducing autoimmunity by using 
artificial components which may break down the body’s natural tolerance to 
sialic acid. As a result vaccine development against serogroup B meningococci 
have sought non-capsular antigens most especially, outer membrane proteins 
(OMP). 
 
OMP vaccines 
Several OMPs have been used as vaccine targets including PorA, PorB and FetA 
[109-111]. These vaccines have had good safety, immunogenicity and efficacy 
profiles. One of the first vaccines to be developed and licensed (1989) against 
serogroup B was VA-MENGOC-BC (Finlay Institute) [110;112]. The vaccine 
was developed to control a Cuban epidemic and was based on OMPs of the 
epidemic strain. Serogroup C capsular polysaccharide was also incorporated 
into the vaccine. The vaccine successfully controlled the Cuban epidemic and 
was also used in Brazil (the state of Sao Paulo), Uruguay and Colombia. This 
led to the development of other tailor-made OMP vaccines to potentially 
control epidemics in Norway and New Zealand [109;111;113]. 
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However a vaccine with much broader coverage was required. The high level of 
diversity among OMPs (since they are exposed to the bacterial environment 
and are therefore under pressure for antigenic change) impeded the 
development of a broad vaccine. Other more conserved sub-capsular vaccine 
candidates were then sought [114]. The advent of reverse vaccinology vastly 
improved the identification of potential serogroup B vaccine candidates [115]. 
These genome-derived neisserial antigens (GNA) were obtained by whole–
genome sequencing of a serogroup B reference strain followed by in silico 
analysis and selection of potential vaccine candidates. 
 
To date the most promising GNA vaccine candidate is a surface–exposed 
lipoprotein, present in all N. meningitidis isolates tested so far, called factor H 
binding protein (fHbp) [116;117]. The human protein, factor H, is a component 
of the alternative complement pathway and is responsible for the down-
regulation of the alternative pathway. Meningococci bind human factor H to 
the bacterial surface and since human factor H retains its activity the alternative 
pathway is down-regulated. The fHbp antibodies act by binding meningococcal 
fHbp. Currently, there are 2 recombinant protein vaccines that are in phase 2 ad 
3 clinical trials. One targets fHbp only while the other is a 5–component vaccine 
that targets GNA1994,GNA2132, GNA2091,GNA1030 and fHbp [117-119].  
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1.6 Molecular characterisation 
 
 
Why characterise? 
 
Characterisation of meningococci is needed to distinguish between strains that 
‘exhibit minimal biochemical and biological differences’ [120]. Characterisation 
data can be used to describe local disease epidemiology which is essential for 
control and management of cases and outbreaks [121]. Comparisons can be 
made to global findings in order to identify spread of hyperinvasive strains 
[122]. Serogroup B characterisation is especially important because of ongoing 
vaccine development.  
 
Molecular techniques 
 
DNA-based methods and technologies have largely replaced serological 
methods of characterisation [123]. The development of DNA methods and 
associated technologies have improved meningococcal disease diagnosis and 
epidemiology. Early antibiotic treatment is essential in cases of meningococcal 
disease [2;109] which compromises culture of the organism. Viable isolates are 
needed for serological serotyping and serosubtyping. Molecular techniques are 
quicker and can be applied to diagnose and characterise culture-negative cases. 
The advent of nucleotide sequencing has made molecular techniques the 
method of choice for diagnostics and epidemiology.  
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1.6.1 PFGE  
 
Pulsed-field gel electrophoresis is used to obtain whole genome fingerprint 
patterns. Patterns are compared in order to determine genetic relatedness 
between isolates. Bacterial cells embedded in agarose plugs are lysed to release 
DNA (Figure 1.7) [124]. The chromosomal DNA is digested, by an infrequently 
cutting (‘rare-site’) restriction endonuclease enzyme, into a small number of 
large fragments [125]. The fragments are resolved on an agarose gel by pulsed-
field electrophoresis which is specific for the separation of large fragments of 
DNA. The electric field in the electrophoresis unit changes direction (Figure 1.7) 
at regular intervals throughout the gel run, this is referred to as switch time. 
This pulsing action assists the DNA fragments in moving through the pores of 
the gel. A molecular weight marker is included on every gel in at least two 
positions (Figure 1.8). 
 
Using specialised software, the gel is captured digitally and the image 
normalised to reduce background noise and visual artifacts, ultimately 
improving the visual quality of the fingerprint. Bands may be manually or 
automatically assigned to each DNA fragment on a fingerprint and a 
dendrogram is generated. The dendrogram shows the genetic relatedness 
amongst a group of strains [126]. Band differences between fingerprints 
represent the occurrence of genetic events [127]. Guidelines for the 
interpretation of PFGE patterns from small collections of outbreak isolates have 
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been suggested [127], however these cannot be directly applied to large 
collections of isolates collected over a long period of time (several years). 
 
Analysis of PFGE patterns from such collections are therefore subject to 
interpretation which may differ from person to person. In addition, 
interlaboratory comparisons are challenging, if not impossible. A pattern-
relatedness breakpoint (i.e. greater than or equal to a certain percentage) is 
applied to the dendrogram to group isolates into clusters. The breakpoint is 
based on findings in the literature as well as the diversity of the organism. 
Clusters are also defined by a minimum number of isolates. Isolates within each 
cluster are considered clonal, deemed to have arisen from a common ancestor. 
Isolates that do not meet the cluster definition are referred to as outliers. 
 
The DNA patterns generated are specific for each strain and therefore PFGE can 
be applied to outbreak investigations and to studies of evolution and structure 
of bacterial populations [128-130]. The use of specialised software resolves 
variation between gels and ultimately improves the accuracy and 
reproducibility of fingerprints [131]. 
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Figure 1.7 Pulsed-field gel electrophoresis. 
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Figure 1.8 Representative PFGE fingerprint patterns of N. meningitidis 
serogroup B isolates. Lanes 1, 10 and 19 contain the molecular weight marker. 
 
Still problems with reproducibility and standardisation between laboratories 
persist [132]. PFGE results are also subject to good quality chromosomal DNA, 
specific and consistent agarose plug, gel and loading conditions. Thus 
comparison of patterns between gels and between laboratories is challenging. 
Furthermore PFGE can only be applied to culture-positive cases. But despite 
these drawbacks the value of PFGE lies in its high discriminatory power, 
especially in outbreak situations, enabling distinction between isolates that may 
have been classified as similar or identical using other characterisation 
techniques, such as multilocus sequence typing. 
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1.6.2 Multilocus sequence typing (MLST) 
 
MLST (Figure 1.9) is a nucleotide-based typing scheme that targets several 
house-keeping genes at various locations within the bacterial chromosome. The 
method was first proposed in 1998 by Maiden and colleagues [133]. The authors 
based MLST on the concept of a previous method, multilocus enzyme 
electrophoresis (MLEE) [134], and used N. meningitidis as the test organism. 
MLEE distinguishes isolates according to the electrophoretic mobility of several 
essential enzymes [135], however it is a laborious procedure and, as is the case 
with PFGE, difficult to compare between laboratories. MLST amplifies and 
sequences the genes that code for essential enzymes. These house-keeping 
genes or enzymes are under selection for conservation of function and therefore 
undergo very slow genetic variation [136]. A slow evolutionary rate makes 
house-keeping genes a reliable marker to determine genetic relationships 
between bacteria over long periods of time.  
 
To improve discriminatory power several loci are selected [136]. A total of 107 
N. meningitidis isolates representative of global strains from invasive cases and 
healthy carriers were chosen for the initial MLST analyses [133]. Initially six of 
eleven genes were chosen based on correlation with MLEE data, fumC was later 
added to the set of N. meningitidis MLST genes. The genes, with their encoded 
enzyme shown in parentheses include: abcZ (putative ABC transporter), adk 
(adenylate kinase), aroE (shikimate dehydrogenase), fumC (fumarate hydratase), 
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gdh (glucose-6-phosphate dehydrogenase), pdhC (pyruvate dehydrogenase 
subunit), pgm (phosphoglucomutase). 
 
 
Figure 1.9 The MLST procedure [136]. 
 
Forward and reverse sequences of each of the seven loci are assembled using 
any DNA sequence alignment software. The resulting nucleotide sequences are 
submitted to the central internet MLST database and assigned an allele number, 
making up the allele profile for that isolate. The isolate is then assigned a 
sequence type (ST) based on the combination of alleles (allelic profile). Isolates 
that are closely related have identical STs or STs that differ at a few loci (usually 
three or less). Unrelated isolates have unrelated STs. Similarly, MLEE 
designated electrophoretic types (ET) to isolates based on a combination of 
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enzyme variants (electromorphs) [134]. Related sequence types can be grouped 
into clusters called clonal complexes [137].  
 
A clonal complex is based on an ancestral ST (founder) and all related STs 
(isolates that share 4 or more alleles with the founder) that are grouped into the 
clonal complex (http://pubmlst.org/neisseria/mlst-info/nmeningitidis/ 
complexes) [136]. Isolates that do not share the required number of alleles with  
existing founders are not assigned to a clonal complex on the MLST database.  
 
An eBURST algorithm (http://eburst.mlst.net) is used to depict relatedness  
within a population based on the ST of each isolate. eBURST divides an MLST 
data set (STs and their allelic profiles) into groups based on a defined group 
definition. A stringent definition where members in a group share ≥6 of 7 alleles 
is recommended. In this case isolates within the group, defined by eBURST, will 
be considered to belong to a clonal complex. Groups can be displayed as an 
eBURST diagram (Figure 1.10). 
 
The primary founder of the group is the ST with the most number of single 
locus variants (SLVs). Double locus variants (DLVs) of the founder are only 
linked if the intermediate SLV is present. For instance, DLV ST11 (Figure 1.10) 
has to contain the same variation as ST10 and an additional variation. Thus 
eBURST provides a hypothesis for descent within a group of isolates. Subgroup 
founders are STs that have a number of SLVs of their own. eBURST uses a 
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bootstrapping procedure to indicate levels of confidence in the assignment of 
founders. An entire MLST dataset can be grouped as a single group by setting 
the group definition to 0 of 7 alleles. A single eBURST diagram can then be 
displayed. This is referred to as a population snapshot. 
 
 
Figure 1.10 eBURST diagram. Primary founders are colored blue.  
The area of the circle is proportional to the prevalence of that ST in the 
input data. STs (SLVs and DLVs) are linked by solid black lines [138]. 
  
MLST data have been added to the expanding internet database since its 
inception in 1998. In 2004, new software was introduced that improved data 
collection and accessibility [139]. The MLST database has specific submission 
procedures and is monitored by curators, ensuring the quality and credibility of 
new sequence data. MLST is a generic nucleotide–based technology and as a 
result generates reproducible and unambiguous data. An advantage that MLST 
has over other bacterial typing schemes is that it is truly portable, available to 
laboratories via the World Wide Web. Most importantly, MLST can be applied 
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to culture-negative specimens [140;141], a common occurrence in 
meningococcal disease due to early antibiotic administration.  
 
Correlation between PFGE and MLST 
Isolates that cluster together on a PFGE dendrogram are considered clonal 
(genetically related) and have therefore arisen from a common ancestor 
[127;142]. If resources are limited, PFGE can be used to screen large numbers of 
isolates in order to get a sense of the overall clonality or diversity of a 
population, following which, random isolates may be selected for further 
characterisation by MLST. PFGE has been shown to be more discriminatory 
than MLST [143]. Therefore, although isolates within a PFGE cluster may have 
differences in their fingerprint patterns, they are still considered to be related 
and should, in most cases, belong to the same clonal complex [45;122]. Thus 
MLST of a few randomly selected isolates within a cluster may be used to infer 
clonal complex for the majority (if not all) isolates within the cluster.  
 
1.6.3 PorA 
 
PorA is a major porin of the meningococcal outer membrane. This surface 
exposed protein is abundant and acts as a pore, allowing nutrients to enter the 
cell [144]. The PorA structure crosses the cell membrane and contains 8 surface 
exposed loops (Figure 1.11). The apex of loops I and IV have been identified as 
areas that undergo frequent antigenic change. These variable regions, termed 
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VR1 and VR2 respectively, are targets for characterisation and immunisation 
strategies [145-148]. 
 
OMPs are in direct contact with the bacterial environment and therefore are 
under strong selection for antigenic change. Since new types are constantly 
generated, serological characterisation using monoclonal antibody panels do 
not always cover all types [11;123]. Molecular serosubtyping is based on 
amplification and sequencing of the variable regions [146;149]. 
 
PorA nomenclature has been standardised [12;146] as follows: P1.VR1,VR2. The 
PorA type is designated by the prefix P1 and variable regions are separated by a 
comma. In addition, each variable region contains families, designated by a 
number, and within each family variants may arise i.e. variants of the original 
family member. Variants are also designated by numbers but separated from 
the original member by a hyphen. Thus the PorA type may be as follows: P1.7-
2,4. PorA nucleotide sequences are submitted to an internet database 
(http://neisseria.org/nm/typing/pora), where the sequence is compared to 
existing sequences on the database for a match. New sequence data are 
submitted to curators of the database for PorA designation.  
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Figure 1.11 Schematic of the amphipathic beta sheet structure of the outer 
membrane proteins PorA and FetA [144;150]. 
 
1.6.4 FetA 
 
FetA is a meningococcal surface-exposed iron receptor that is expressed under 
conditions of iron limitation. Free iron concentrations in the human body are 
low because iron is bound to storage and transport proteins such as 
hemoglobin, ferritin, transferrin and lactoferrin. Since iron is essential for 
bacterial growth [151], bacteria have developed iron-accumulating strategies. 
Some bacteria produce and secrete siderophores, organic chelating agents that 
solubilise iron and transport it back into the cell. The meningococcus acquires 
iron directly from lactoferrin [152] (at mucosal surfaces) and transferrin [153] (in 
serum). 
 
Since the condition of iron limitation is met in the human body, the expression 
of FetA, previously known as FrpB [150;154], is ensured. This 70kDa protein is 
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employed in classification systems [12] and as a vaccine target. While iron 
limitation is required for expression, only a few isolates lack the genes encoding 
FetA [155]. Deletion of the feta gene seems to be a sporadic event that is not 
maintained. 
 
A topology model was proposed in 1995 [150]. The FetA protein structure has 
13 surface-exposed loops (Figure 1.11). The largest of these, Loop 7, is a region 
of variability and is targeted for characterisation. The variable region (VR) is 
amplified and sequenced. FetA sequence data are submitted to a FetA internet 
database (http://neisseria.org/nm/fetA) for type designation. FetA types are 
divided into families and within each family there are variants. A family is 
designated by a number and preceded by an F (e.g. F1) and the variant follows 
after a hypen, e.g. F1-5. Like PorA typing, FetA typing is a generic sequence-
based method and as a result provides portable and unambiguous 
characterisation data. 
 
1.7 Molecular epidemiology 
 
Portable DNA-based methods have vastly improved global meningococcal  
surveillance [156]. Invasive clones can be rapidly and unambiguously 
monitored as they spread between countries and across continents. Molecular 
surveillance is also important to track changes in population structure and 
evolution of N. meningitidis. 
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1.7.1 Genetic diversity in meningococcal populations 
 
 
A naturally transformable bacterium  
Bacterial cells reproduce asexually by binary fission resulting in daughter cells 
that are identical to the parent cell [157]. During cell division mutations occur 
giving rise to genetic variation. Mutations are maintained through successive 
generations but as the population grows selection processes favour isolates with 
certain mutations while removing others. The result is a relatively clonal 
population. 
 
However bacterial cells are also able to exchange genetic material ‘horizontally’ 
[158;159]. Horizontal gene transfer is the exchange of small fragments of genetic 
material between cells that do not share the same parent and is referred to as 
‘localised sex’. If this process occurs at a high frequency, the clonal structure of 
the population is disrupted. Transformation (uptake of DNA fragments from 
the environment by competent cells and integration of the fragment into host 
DNA) is one of the ways by which horizontal gene transfer occurs. N. 
meningitidis is a naturally competent bacterium, able to take up homologous 
DNA from the environment [157;158;160], and incorporate it into the 
chromosome by recombination.  
 
Phase variation 
Phase variation brings about genetic diversity through mutation [161]. The 
meningococcal genome contains repetitive sequences of DNA that control the 
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expression of genes through a process called phase variation. The repeat 
sequences may be located anywhere in the genome and are used by the bacteria 
to adapt quickly to their current environment. Mutations are passed on to 
successive generations and selection forces choose variants with increased 
fitness. 
 
Thus, a high degree of genetic diversity is brought on by increased rates of 
recombination and phase variation, in the meningococcus [123;162]. Despite 
this, clonal complexes within meningococcal populations persist over time and 
geographical distance [163]. So while N. meningitidis serogroup B isolates are 
extremely diverse, there are natural selective forces (as yet undetermined) that 
work to maintain a clonal population structure [164]. 
 
1.7.2 Invasive clonal complexes 
 
When describing molecular disease epidemiology, isolates are often referred to 
by the clonal complex to which they belong (designated as ST-clonal complex 
number) [165]. Where available the corresponding ET lineage is included in the 
nomenclature (e.g ST-32/ET-5 complex). Carriage isolates are more genetically 
diverse and so belong to a greater number of clonal complexes [17;121;166], 
many of which are not associated with invasive isolates. Globally, the majority 
of global invasive disease is caused by strains that belong to a few clonal 
complexes refered to as hyperinvasive lineages [21;156;167]. Furthermore, 
clonal complexes may have a dominant serogroup, PorA and FetA types (Table 
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1.1). With regard to serogroup B invasive disease there are two important 
invasive lineages, ST-32/ET-5 and ST-41/44/lineage 3 [21]. Clones of these 
lineages have caused meningococcal outbreaks since the early 1970s (Table 1.2). 
 
1.7.3 South Africa 
 
From 1973 to 1978 circulating serogroup B clones included ET26, ET27 and ET10 
from clonal complexes ST-11/ET-37 and ST-8/Cluster A4 [168] with no 
evidence of the ST-32/ET-5 complex [169;170] (Figure 1.12). From 1977 through 
1979 South Africa experienced an increase in incidence of meningococcal 
disease. Isolates from cases during the outbreak revealed ET10 as the dominant 
clone. MLEE of a selection of serogroup B isolates (n=21) identified two strains 
of the ST-32/ET-5 complex (B:NT:P1.15) in South Africa in 1980 [169-171].  
 
Orren et al. [172] analysed 124 routinely collected invasive isolates from the 
Western Cape from 1985 to 1990. A total of 22 isolates belonged to clonal 
complex ST-32/ET-5. The most common strain among routine isolates was 
B:4:P1.15. Then a local molecular epidemiology study by Coulsen et al. [79] on 
meningococcal isolates collected through our national laboratory-based 
surveillance system from August 1999 through July 2002, showed, once again, 
the circulation of the ST-32/ET-5 clone in the country. The Coulson study also 
identified the presence of ST-41/44/lineage 3 strains in South Africa. 
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Table 1.1 Important N. meningitidis clonal complexes compiled from the MLST database (February 6, 2009) [165].  
 
Clonal complex MLEE 
designation 
No. of isolates No. of STs Dominant serogroups (%) Dominant 
PorA 
Dominant 
FetA 
ST-1 complex Subgroup I/II 204 49 A(97) 5-2,10 F3-5 
ST-5 complex Subgroup III 627 33 A(99) 20,9 F3-1 
ST-8 complex Cluster A4 283 107 B(51),C(35) 5-1,2-2 F3-6 
ST-11 complex ET-37 complex 1142 239 C(57),W135(24),B(12) 5,2 F3-6 
ST-18 complex Cluster J1 208 175 B(85) 22,14 F3-6 
ST-22 complex  363 243 W135(52),NG(25) 18-1,3 F4-1 
ST-23 complex Cluster A3 385 154 Y(62),NG(18) 5-1,2-2 F4-1 
ST-32 complex ET-5 complex 1028 350 B(85) 19-15 F5-1 
ST-35 complex  329 214 B(59),NG(25) 22-1,14 F4-1 
ST-41/44 complex Lineage 3 1796 1274 B(70) 7-2,4 F1-5 
ST-53 complex  272 93 NG(76) 7-2,30 F1-7 
ST-60 complex  225 148 B(30),29E(22),NG(19) 5,2 F1-7 
ST-103 complex  127 84 B(26),NG(22),C(16) 18-1,3 F3-9 
ST-162 complex  140 63 B(74),NG(13) 22,14 F5-9 
ST-167complex  201 144 Y(47),NG(36) 5-1,10-4 F3-4 
ST-198 complex  166 76 NG(76) 18,25-15 F5-5 
ST-213 complex  187 165 B(74),NG(16) 22-14 F5-5 
ST-254 complex  148 107 NG(35),B(24),29E(12) 5-1,16 F1-7,F3-6 
ST-269 complex  415 312 B(73) 22,9 F5-1 
ST-334 complex  106 64 C(58),B(33) 5-1,2-2 F1-5 
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Table 1.2 Genotypes of N. meningitidis serogroup B epidemic strains [21]. 
 
Location Time period Antigenic profile 
ST-32/ET-5 complex   
Norway 1960s and 1970s B:15:P1.7,16 
Spain 1970s B:4:P1.19,15 
Cuba, Brazil 1980s B:4:P1.19,15 
Chile 1980s B:15:P1.3 
Oregon, U.S. 1990-2000s B:15:P1.7,16 
ST-41/44/lineage 3 complex   
Netherlands 1980s B:4:P1.4 
New Zealand 1990s-present B:4:P1.7b,4 
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Figure 1.12  Timeline depicting clones identified in South Africa.
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1.8 Aim  
 
To update serogroup B molecular epidemiology data by investigating the 
molecular diversity of circulating Neisseria meningitidis serogroup B isolates in 
South Africa from January 2002 through December 2006. 
 
1.9 Objectives 
 
1. To characterise all Neisseria meningitidis serogroup B isolates (n=307) 
available from cases reported to the national laboratory-based 
surveillance system from January 2002 through December 2006, using 
PFGE. 
2. To fully characterise all serogroup B isolates (n=58) from one year (2005) 
using MLST, porA and fetA typing. 
3. To characterise randomly selected serogroup B isolates from other 
collection years using MLST, porA and fetA typing.  
4. To compare the above results to existing PFGE and MLST data for 
serogroup B isolates collected from August 1999 through July 2002. 
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2 METHODS 
 
 
 
Figure 2.1 A brief overview of the methodology used in this study. 
 
 
2.1 Bacterial isolates 
 
N. meningitidis serogroup B isolates were obtained from the Respiratory and 
Meningeal Pathogens Research Unit (RMPRU) at the National Institute for 
Communicable Diseases (NICD), of the National Health Laboratory Service 
(NHLS), Johannesburg, South Africa. The unit conducts ongoing national 
laboratory-based surveillance for invasive disease caused by bacterial respiratory 
 The χ2 test for trend was used to assess 
linear trend over time. P values <0.05 
were considered statistically significant. 
 1627/2144  cases had viable isolates, and 307 were 
identified as serogroup B 
 
 All available serogroup B isolates (n=307) were 
characterised by pulsed-field gel electrophoresis (PFGE). 
 
 Clusters were defined as ≥5 isolates sharing ∼80% 
similarity on the PFGE dendrogram. 
 PorA, FetA and multilocus sequence 
(MLST) typing were performed on 
isolates from 2005 (n=57) and randomly 
selected isolates (n=25) from other years. 
 
 Cases of invasive meningococcal disease reported to an ongoing national 
laboratory-based surveillance system from January 2002 through  
December 2006 (n=2144).  
 Case definition:  
Identification of meningococcus from any normally sterile-site specimen: 
culture positive or positive on Gram stain, antigen detection (latex 
agglutination) and/or PCR. 
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pathogens including N. meningitidis. Viable isolates, together with patient and 
specimen details, are routinely submitted to the unit from approximately 180 
private, public, military and mining hospital laboratories country wide (Appendix 
A3). In 2003, surveillance was enhanced at 26 sentinel sites (Appendix A1) and cases 
from these sites were accompanied by additional patient data such as final 
outcome, discharge diagnosis, severity of illness, HIV status, history of 
tuberculosis treatment, and antibiotic use prior to and during admission. Data 
were collected from cases by on-site surveillance officers according to a 
standardised case report form (Appendix A2). Surveillance officers gathered 
information by interviewing patients or patient contacts, and/or from available 
medical records. 
 
Once received, isolates were cultured from Dorset egg transport media [173] 
(Diagnostic Media Products, a division of the NHLS, Johannesburg, South Africa) 
onto Columbia agar (Oxoid Ltd, Basingtoke, United Kingdom) supplemented with 
5% horse blood (South African Vaccine Producers, a division of the NHLS, 
Johannesburg, South Africa) and incubated at 37°C in 5% CO2. Isolates were 
serogrouped by slide agglutination by first using polyclonal antisera to capsular 
polysaccharides A, B, C and D and, X, Y, Z and W135 (Remel Europe Ltd, 
Dartford, England). Then a reaction to determine the precise serogroup was 
carried out using monoclonal anitisera (Remel Europe Ltd, Dartford, England). 
Pure cultures were prepared for long term storage by suspension in 1 ml of 10% 
skim milk (Oxoid Ltd, Basingtoke, United Kingdom) and stored at -70°C. 
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2.2 Case definition 
 
Cases were defined as patients with N. meningitidis identified from normally 
sterile body fluids (e.g. blood, cerebrospinal fluid, joint fluid and pleural fluid). 
 
2.3 Pulsed-field gel electrophoresis 
 
PFGE was carried out as previously described by Gautom [124]. A total of 307 
serogroup B isolates causing invasive meningococcal disease in South Africa from 
January 2002 through December 2006 were available for PFGE. 
 
2.3.1 Plug preparation 
 
Each isolate was sub-cultured from -70°C onto 5% horse blood agar and incubated 
overnight at 37ºC in 5% CO2. Cultures were then directly suspended with cotton 
swabs into 1.5 ml of TE buffer (Appendix B3) and adjusted to a cell concentration of 
0.5-1.0 using a Dade Microscan Turbidity Meter (Dade, California, USA). 200 µl of 
cell suspension was transferred to a 1.5 ml microcentrifuge tube, to which 20 µl of 
10 mg/ml lysozyme (Sigma Aldrich, Steinheim, Germany) (Appendix B4) and 10 µl 
of 20 mg/ml proteinase-K (Roche, Mannheim, Germany) (Appendix B5) were 
added for cell lysis. Cell suspensions were incubated at 37°C for 15 min. Seakem 
Gold agarose (Lonza, Rockland, USA) solution was made up to a 1.2% 
concentration (Appendix B8) and maintained in a 55°C waterbath. Following 
incubation, 20 µl of 10% SDS (Appendix B9) was added to each cell suspension. 
Finally, 260 µl of the melted 1.2%  Seakem Gold agarose was mixed into each 
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bacterial suspension. The bacterium-agarose mixture was immediately pipetted 
into a plug mould and allowed to solidify for 20 to 30 min at room temperature. 
The solidified plug was transferred into 2 ml of Cell Lysis Buffer (Appendix B10) 
and incubated in a shaking water bath at 50°C for a minimum of 2 h. After 
incubation, cell lysis buffer was poured off and plugs were washed in 8 to 10 ml of 
preheated (50°C) sterile water for 15 min at 50°C. The plugs were then washed 3 
times (15 min each) with 8 to 10 ml preheated (50°C) TE buffer. All washes were 
done in an oscillating water bath at 50°C. Plugs were subsequently transferred to 2 
ml of TE buffer (room temperature) and stored at 4°C for further use.  
 
2.3.2 Restriction endonuclease digestion 
 
For restriction endonuclease digestion, 4 mm thick slices of the plug were 
incubated in 100 µl of 1x restriction buffer (Appendix B11) at 37°C for 15 min. 
Restriction buffer was removed and DNA within the agarose plug was digested 
with 100 µl NheI restriction enzyme (Roche Diagnostics, Mannheim, Germany) 
cocktail (Appendix B12).   
 
2.3.3 Electrophoresis 
 
Digested slices were then carefully loaded onto a comb, placed onto a gel tray and 
allowed to air dry for 5 to 8 min. A commercially available DNA lambda ladder 
(Bio-Rad, Hercules, CA) was used as a molecular marker and was placed in the 
first and last lanes on the gel. A 160 ml 1.1% Seakem Gold agarose solution was 
prepared. The solution was placed on a stirrer-hot plate and equilibrated to 54°C to 
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56°C. The agarose solution was poured into the gel tray and allowed to set. 
Approximately 3 L of 0.5x TBE buffer (Appendix B7) was equilibrated to 14°C in the 
PFGE chamber. Once solidified the gel was placed into the electrophoresis 
chamber. Electrophoresis was performed using the following conditions: 6 V/cm, 
120° angle and switch times of 1-30 s for 16 h followed by 0.1-6 s for 4 h.  
 
2.3.4 Visualisation and gel capture  
 
Upon completion of electrophoresis, gels were stained in 300 ml of ethidium 
bromide solution (Appendix B13) for 15 min. The gel was washed 3 times (for 10 
min each) in ~300 ml of distilled water and viewed on an ultraviolet 
transilluminator for fingerprint patterns. The gel was photographed using a 
polaroid camera and digitally captured using a gel documentation system 
(Vacutec, Johannesburg, South Africa). 
 
2.3.5 PFGE image analysis 
 
Digital images were analysed using GelComparTM v6.1 software (Applied Maths, 
Kortrijk, Belgium). Fingerprints were added to an existing N. meningitidis PFGE 
database. This database contained the following fields: isolate number, serogroup, 
collection year, collection date, province, sequence type, clonal complex, PorA 
type, and FetA type. Genetic relatedness was determined by creating dendrograms 
using the unweighted pair group method with arithmetic averages (UPGMA) and 
Dice coefficient using an optimisation of 1.5% and 1.5% position tolerance. A 
cluster was defined as five or more isolates that shared ∼80% similarity on the 
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dendrogram [79;126;127]. Isolates that not meet the cluster definition were referred 
to as outliers. 
 
2.4 Multilocus sequence typing (MLST) 
 
The MLST procedure was based on the method described on the MLST website: 
(http://pubmlst.org/neisseria/). Approximately 10% of the total number of 
isolates available for PFGE (n=307), were randomly selected for MLST. A web-
based random number generator (http://www.random.org/sequences/) was 
used to generate a selection of 30 isolates. An additional four isolates from 2002 
(n=2) and 2003 (n=2) had MLST data only. MLST was also performed on all 
serogroup B isolates from 2005 (n=58).  
 
2.4.1 DNA extraction  
 
Crude DNA extracts were prepared by suspending a loopful of overnight culture 
in 100 µl sterile distilled water. Cell suspensions were boiled at 95°C for 10 min to 
lyse the cells, followed by centrifugation at 12 000 rpm for 15 s. The supernatant 
contained the DNA.  
 
2.4.2 PCR of house-keeping genes 
 
PCR was used to amplify internal fragments of the following seven house-keeping 
genes: abcZ (putative ABC transporter), adk (adenylate kinase), aroE (shikimate 
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dehydrogenase), fumC (fumarate hydratase), gdh (glucose-6-phosphate 
dehydrogenase), pdhC (pyruvate dehydrogenase subunit), pgm 
(phosphoglucomutase). The primer pairs used for PCR amplification are depicted 
in Table 2.1.  
 
Table 2.1 Meningococcal MLST PCR primers.  
 
Gene Primer 
abcZ abcZ-P1C 5-TGTTCCGCTTCGACTGCCAAC-3 
 abcZ-P2C 5-TCCCCGTCGTAAAAAACAATC-3 
adk adk-P1B 5-CCAAGCCGTGTAGAATCGTAAACC-3 
 adk-P2B 5-TGCCCAATGCGCCCAATAC-3 
aroE aroE-P1B 5-TTTGAAACAGGCGGTTGCGG-3 
 aroE-P2B 5-CAGCGGTAATCCAGTGCGAC-3 
fumC fumC-P1B 5-TCCCCGCCGTAAAAGCCCTG-3 
 fumC-P2B 5-GCCCGTCAGCAAGCCCAAC-3 
gdh gdh-P1B 5-CTGCCCCCGGGGTTTTCATCT-3 
 gdh-P2B 5-TGTTGCGCGTTATTTCAAAGAAGG-3 
pdhC pdhC-P1B 5-CCGGCCGTACGACGCTGAAC-3 
 pdhC-P2B 5-GATGTCGGAATGGGGCAAACA-3 
pgm pgm-P1 5-CTTCAAAGCCTACGACATCCG-3 
 pgm-P2 5-CGGATTGCTTTCGATGACGGC-3 
 
PCR cycling conditions were as follows:  
              1 cycle : 94°C for 2 min 
              25 cycles : 94°C - 1 min, 56-62°C - 1 min, 72°C - 1 min 
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              1 cycle : 72°C for 5 min 
Annealing temperatures vary for the different primer sets : abcZ, adk, pdhC and 
gdh anneal at 58°C, while aroE, fumC and pgm anneal at 56°C, 60°C, and 62°C 
respectively. 
 
2.4.3 Cleanup of PCR products 
 
PCR products were purified using the MSB Spin PCRapace purification kit 
(Invitek, Berlin, Germany). Clean up was performed as per the manufacturer’s 
instructions. Briefly, the PCR sample was mixed thoroughly with binding 
buffer. The solution was then transferred onto a spin filter and centrifuged for 
3 min at 12 000 rpm. Elution buffer was added directly onto the center of the 
spin filter in order to elute the PCR fragments. The spin filter with elution 
buffer was incubated at room temperature for 5 min before centrifuging for 1 
min at 10 000 rpm. The eluate, containing the purified PCR fragments, were 
stored at 4°C. 
 
2.4.4 Cycle sequencing 
 
Following amplification, sequencing of both forward and reverse strands was 
carried out using the Big Dye v3.1 Cycle Sequencing Kit (Applied Biosystems, 
Foster City, CA, USA) and an ABI 3130 Genetic Analyser (Applied 
Biosystems). Sequencing reactions  for each strand (forward and reverse) were 
set up and prepared to a final volume of 10 µl, using the following 
components: 1 µl Terminator Ready Reaction Mix, 1.5 µl 5x Sequencing Buffer, 
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0.5 µl purified DNA, 0.5 µl of a 0.5 µM forward or reverse primer and 6.5 µl 
sterile deionised water. Reaction conditions were as follows : 
       1 cycle : 94°C for 1 min 
       25 cycles : 95°C - 30 s, 50°C - 20 s and  60°C - 4 min 
Sequencing primers are depicted in Table 2.2.  
 
Table 2.2 Meningococcal MLST sequencing primers.  
 
Gene Primer 
abcZ abcZ-S1A 5-AATCGTTTATGTACCGCAGR-3 
 abcZ-S2 5-GAGAACGAGCCGGGATAGGA-3 
adk adk-S1A 5-AGGCWGGCACGCCCTTGG-3 
 adk-S2 5- CAATACTTCGGCTTTCACGG-3 
aroE aroE-S1A 5- GCGGTCAAYACGCTGRTK-3 
 aroE-S2 5-ATGATGTTGCCGTACACATA-3 
fumC fumC-S1 5-TCCGGCTTGCCGTTTGTCAG-3 
 fumC-S2 5-TTGTAGGCGGTTTTGGCGAC-3 
gdh gdh-S3 5-CCTTGGCAAAGAAAGCCTGC-3 
 gdh-S4C 5-RCGCACGGATTCATRYGG-3 
pdhC pdhC-S1 5-TCTACTACATCACCCTGATG-3 
 pdhC-S2 5-ATCGGCTTTGATGCCGTATTT-3 
pgm pgm-S1 5-CGGCGATGCCGACCGCTTGG-3 
 pgm-S2 5-GGTGATGATTTCGGTYGCRCC-3 
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In order to remove unincorporated dye terminators from the sequencing 
reaction, cycle sequencing products were cleaned using one of two kits : DyeEx 
2.0 Spin Kit (Qiagen Inc., CA, USA) or NucleoSEQ (Macherey-Nagel, Düren, 
Germany). Spin columns with a hydrated gel matrix were centrifuged at 2700 
rpm for 3 min. Cycle sequencing samples were then added drop-wise to the 
center of the dehydrated gel matrix and centrifuged at 3000 rpm for 5 min to 
recover purified sequences. Samples were dried in a vacuum centrifuge and 
resuspended in 12 µl of Hi-Di Formamide (Applied Biosystems). 10 µl of each 
sample was loaded into a 96-well reaction plate for capillary injection 
electrophoresis.  
 
2.4.5 Analysis of sequences 
 
Sequence data were analysed using DNAStar Lasergene v7 software (Madison, 
Wisconsin, USA). Sequences were trimmed to the appropriate length using a 
reference sequence (for each gene of interest) obtained from the MLST website. 
Sequences were submitted to the MLST database (http://pubmlst.org/ 
nesseria/allelicprofile/STdatabase) for allele and sequence type assignment. 
eBURST diagrams depicting genetic relatedness by sequence type were 
generated using software at http://eburst.mlst.net. New allele profiles, 
resulting from the identification of a new allele or new allelic combination, 
were submitted to the MLST database for designation of a new ST. 
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2.5 PorA typing 
 
PorA typing was done as described by Sacchi and collegues [174]. All randomly 
selected serogroup B isolates (n=30), isolates with existing MLST data (n=4) and 
those from 2005 (n=58), were selected for analysis by PorA typing. The variable 
regions of PorA (VR1 and VR2) were amplified by PCR using primers listed in 
Table 2.3. 
 
Table 2.3 PorA PCR and sequencing primers. 
 
PCR cycling conditions were as follows: 
       1 cycle : 94°C for 1 min 
       30 cycles : 94°C - 1 min, 60°C - 30 s, 72°C - 2 min 
       1 cycle : 72°C for 5 min 
Nucleotide sequences were determined as described in section 2.4.4. Sequence 
data was analysed using DNAStar Lasergene v7 software. Sequences were 
     Primer 
PCR P14 5-GGGTGTTTGCCCGATGTTTTT 
P22 5-TTAGAATTTGTGGCGCAAACCGAC-3 
SequencingVR1 U86 5-GCCCTCGTATTGTCCGCACTG-3 
435 5-TTGCTGTCCCAAGGATTAATGGC-3 
SequencingVR2 435 5-GCCATTAATCCTTGGGACAGCAA-3 
773 5-GGCATAGTTCCCGGCAAAACCGCCAT-3 
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submitted to http://neisseria.org/nm/porA to identify PorA VR1 and VR2 
regions. 
 
2.6 FetA typing 
 
FetA typing was performed as described on the Neisseria.org website 
(http://neisseria.org/nm/typing/feta/information). All randomly selected  
serogroup B isolates (n=30), those with existing MLST data (n=4) and those from 
2005 (n=58), were selected for FetA typing. The variable region of FetA was 
amplified by PCR using primers as depicted in Table 2.4. 
 
PCR cycling conditions were as follows: 
       1 cycle : 94°C for 1 min 
       30 cycles : 94°C - 1 min, 55°C - 1 min, 72°C - 90 s 
       1 cycle : 72°C for 1 min 
 
Nucleotide sequences were determined as described in section 2.4.4. Sequence 
data were analysed using DNAStar Lasergene v7 software. Sequences were 
submitted to http://neisseria.org/nm/fetA to identify FetA types. 
 
 
 
 
 
 
  Methods 
 54 
Table 2.4  FetA PCR and sequencing primers. 
 
 
2.7 Data analysis 
 
Age-specific incidence rates were calculated for the last year (2006) of the study 
period. The total number of laboratory-confirmed cases reported to RMPRU in 
2006 were divided by mid-year total population estimates provided by Statistics 
South Africa (http://www.statssa.gov.za/publications/ P0302/P03022006). 
 
The following demographic data were captured on a Microsoft Excel spreadsheet: 
isolate collection date, serogroup, province, PFGE cluster, sequence type, clonal 
complex, PorA type and FetA type, patient gender, race, age category, outcome 
(died vs recovered), and specimen type (from which the organism was isolated). 
Comparisons by year, geographic area, PFGE cluster and sequence data were 
made. Differences in proportion were calculated using the χ2-test (Mantel-Haentzel 
or Fisher’s exact test), while trend over time was evaluated using the χ2-test for 
trend. P values of less than 0.05 were considered significant. Statistical tests were 
performed using Epi Info, version 6.04d (Centers for Disease Control and 
Prevention, GA, USA).  
 Primer 
PCR S1 5-CGGCGCAAGCGTATTCGG-3 
S8 5-CGCGCCCAATTCGTAACCGTG-3 
Sequencing S12 5-TTCAACTTCGACAGCCGCCTT-3 
S15 5-TTGCAGCGCGTCTACAGGCG-3 
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2.8 Ethics 
 
Ethics approval for national surveillance (PRC Reference no. 000105) and ethics 
clearance for this project (Protocol No. M080701) (Appendix C), were obtained from 
the Human Research Ethics Committee (Medical) at the University of the 
Witwatersrand, Johannesburg. 
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3 RESULTS 
 
3.1 Epidemiology of meningococcal disease in South Africa, 2002-2006 
 
For the study period, January 2002 through December 2006, 2144 cases (Figure 3.1) of 
laboratory-confirmed meningococcal disease were reported to RMPRU. Gauteng 
(1234/2144, 58%) and the Western Cape (354/2144, 17%) recorded the highest 
number of cases among the 9 provinces (Figure 3.2). Of 2144 cases, 1627 (76%) had 
viable isolates and were therefore serogrouped (Table 3.1). Serogroup B (307/1627, 
19%) and serogroup W135 (702/1627, 43%) were collectively responsible for 62% of 
cases in South Africa. Serogroup B prevalence decreased from 24% in 2002 to 14% in 
2006 (p=<0.001). Serogroup B was most common in the Western Cape and W135 in 
Gauteng. Serogroup B cases were reported in all provinces (Figure 3.3).  
 
Age was known for 94% (2005/2144) of all cases and 97% (299/307) of serogroup B 
cases. Children <5 years of age were at highest risk for meningococcal disease (Figure 
3.4). With regard to gender, males seemed to be more affected by the disease than 
females but this was not significant (all disease, p=0.256 and serogroup B disease, 
p=0.685) (Table 3.2). Overall, 1418/2144 (66%) of all meningococcal disease cases 
were diagnosed by identification of the organism on CSF specimens alone, 249 (12%) 
from CSF and blood specimens, and 469 (22%) from blood specimens (without CSF). 
A minority of cases were identified from specimens that were not CSF or blood (2 
cases from pleural fluid, 6 cases from synovial fluid or joint tissue). Serogroup B 
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isolates were cultured from predominantly CSF specimens (194/307, 63%) and CSF 
and blood specimens (43/307, 14%), while 70/307 (23%) were cultured from blood 
specimens alone. The proportion of cases of serogroup B identified from CSF 
specimens was not different to the proportion of non-serogroup B isolates from the 
same specimen (237/307, 77% vs 1021/1320, 77%, p=0.955). Of 307 serogroup B 
isolates received, only 100 were from cases at enhanced surveillance sites and had 
additional clinical details. Of these, 99 had documented clinical diagnosis: 90 (91%) 
with meningitis, and 9 with signs of generalized sepsis without meningitis. The final 
outcome of serogroup B disease was known for 97/100, and the case-fatality ratio 
was 9/97 (9%). 
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 Figure 3.1 Number of cases of meningococcal disease in South Africa as reported to RMPRU, 2002-2006 (n=2144). 
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Figure 3.2 Number of cases of meningococcal disease by province, South 
Africa, 2002-2006 (n=2144). 
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Table 3.1 Serogroups causing invasive meningococcal disease in South Africa, 
2002-2006.  
 
Year Serogroup No datab 
  A B C Y W135 X Z NG  
2002 58 47 20 41 24 1 - 1 77 
2003 87 76 31 43 26 1 2 - 102 
2004 57 62 31 53 77 1 - - 79 
2005 24 58 21 52 257 2 - - 129 
2006 4 64 41 45 318 1 - 1 130 
 Total 230 307 144 234 702 6 2 2 517 
NOTE:1627/2144 (76%)  viable isolates were serogrouped. NG – non-groupable isolates. 
b Isolate not available for serogrouping 
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Figure 3.3 Number of cases of serogroup B meningococcal disease by province, 
South Africa, 2002-2006 (n=307). 
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Figure 3.4 Age-specific incidence rates for meningococcal disease, South Africa, 
2006. 
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Table 3.2 Gender distribution of meningococcal disease, South Africa, 2002-2006. 
 
 
 
 
 
 
 
 
 
 
 
Year All disease   Serogroup B disease  
 Male (%) Female (%) Unknown (%) Total  Male (%) Female (%) Unknown (%) Total  
2002 151 (56) 114 (42) 4 (1) 269  22 (46) 24 (51) 1 (2) 47  
2003 221 (60) 138 (38) 9 (2) 368  43 (57) 32 (42) 1 (1) 76 
2004 204 (57) 148 (41) 8 (2) 360  34 (55) 25 (40) 3 (5) 62  
2005 306 (56) 223 (41) 14 (3) 543  35 (60) 21 (36) 2 (3) 58  
2006 319 (53) 271 (45) 14 (2) 604  35 (55) 27 (42) 2 (3) 64  
Total 1201 (56) 894 (42) 49 (2) 2144  169 (55) 129 (42) 9 (3) 307 
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3.2 Molecular characterisation of N. meningitidis serogroup B isolates, 2002-2006 
 
 
From January 2002 through December 2006, 307 viable N. meningitidis serogroup B 
isolates from invasive cases were collected by the surveillance network. Of these, 305 
(98%, 305/307) were available for characterization by pulsed-field gel electrophoresis 
(two isolates were no longer viable from their -70°C stocks). Of the 305 isolates 
characterized by PFGE, three isolates were excluded from the analysis due to poor 
fingerprint patterns.  
 
On average, the restriction endonuclease enzyme NheI, digested DNA into 15-20 
fragments (Figure 1.8). A total of 260 fingerprint patterns were generated among the 
302 isolates. Applying a ≥79% pattern relatedness breakpoint to the dendrogram, 
isolates were divided into 13 PFGE clusters (206/302, 68%), and 96 unrelated isolates 
(96/302, 32%). Clusters were designated B1 to B13 (Figure 3.5) (Appendix D). 
 
Approximately 10% of serogroup B isolates (n=302) were randomly selected for 
MLST, PorA and FetA characterisation, (2002, n=4; 2003, n=5; 2004, n=5; 2005, n=5; 
and 2006, n=11). Four serogroup B isolates from 2002 (n=2) and 2003 (n=2) had 
existing MLST data (only) from other studies and were also included in the analysis. 
These isolates were further characterised by PorA and FetA typing.  
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MLST results were obtained for 33/34 isolates. Four of seven genes could not be 
amplified for the one isolate. A total of 24 STs were identified. The most common 
clonal complexes were ST-41/44/lineage 3 (9/33) and ST-32/ET-5 (6/33) (Table 3.3). 
Overall most isolates were not assigned to a clonal complex (12/33). 
 
Table 3.3 Clonal complexes of N. meningitidis serogroup B isolates, 2002-2006. 
 
Clonal complex n (%) STs (n) 
No complex 
 
12 (36) 
 
ST3839, ST4240, ST4243, ST6688 (3), ST6990, ST6992 
ST7222, ST7223, ST7392, ST7946 
ST-41/44/lineage 3 9 (27) ST41, ST43, ST154 (2), ST6590 (3), ST6698, ST7945 
ST-32/ET-5  6 (18) ST33 (5), ST6589 
ST-865 2 (6) ST6687, ST7195 
ST-35  1 (3) ST2437 
ST-334  1 (3) ST7978 
ST-269  1 (3) ST283 
ST-1157  1 (3) ST1157 
Total 33  
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 *Outliers (n=96) 
 
B3 (n=19)       No complex (n=3); ST-35 (n=1) 
B11 (n=5) 
B2 (n=31)       ST-41/44/lineage 3 (n=4) 
B1 (n=76)      ST-32/ET-5 (n=6) 
B5 (n=15)      ST-865 (n=2) 
 
B9 (n=5) 
B4 (n=15)      ST-41/44/lineage 3 (n=1); 
                       no complex (n=1) 
 
B12 (n=5)       ST-334 (n=1) 
B6 (n=11)      
PFGE 
clusters 
79% MLST 
clonal complex 
 
B7 (n=8)         ST-41/44/lineage 3 (n=1) 
B13 (n=5) 
B10 (n=5)      ST-269 (n=1) 
B8 (n=6)        ST-41/44/lineage 3 (n=2) 
Figure 3.5 PFGE dendrogram with MLST clonal complex information, representing the genetic 
relationship among serogroup B meningococci causing invasive disease in South Africa, 2002-2006 
(n=302). 
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3.2.1 PFGE 
 
Cluster B1  
The largest cluster, B1, accounted for 25% (76/302) of isolates (Figure 3.5). There were 
54 distinct PFGE fingerprint patterns within the cluster. B1 isolates were present 
throughout the study period and decreased over time, from 43% (20/47) in 2002 to 
13% (8/62) in 2006 (p = 0.003) (Table 3.4 and Figure 3.6). Isolates were present in 4/9 
provinces (Table 3.5), but were most common to the Western Cape (58/76, 76%). 
MLST data were available for six isolates (6/76, 11%), 3 were randomly selected and 3 
had available MLST data. All isolates belonged to cc ST-32/ET-5. Two STs, differing 
by a single allele were identified, namely ST33 (n=5) and ST6589 (n=1). Isolates 
expressed PorA types P1.19,15 (n=3) and P1.12-1,13-1 (n=3). FetA types included F5-1 
(n=5) and F3-7 (n=1).  
 
Cluster B2 
Cluster B2 accounted for 10% (31/302) of isolates (Figure 3.5). Present throughout the 
study period, B2 isolates showed no significant change over time [6% (3/47) in 2002 
compared to 16% (10/62) in 2006 (p = 0.4)] (Table 3.4 and Figures 3.6). B2 isolates 
were present in 4/9 provinces (Table 3.5), but were most common to Gauteng (18/31, 
58%). Selected isolates from B2 (4/31, 13%) belonged to clonal complex ST-
41/44/lineage 3. Three sequence types were identified, ST154 (n=2), ST6698 (n=1) 
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and ST41 (n=1). ST6698 and ST41 differed from ST154 by 1 allele. All 4 isolates 
expressed the same PorA, P1.7-2,4, and FetA, F1-5 type. 
 
Table 3.4 Meningococcal serogroup B PFGE clusters, South Africa, 2002-2006. 
 
 
NOTE: Isolates within each cluster were compared to all other isolates (ie. those in clusters and 
outliers) over the 5-year period. Significant p values are in bold. 
 
 
 
 
 
 
 
 
Cluster 2002 2003 2004 2005 2006 p 
                   n n n n n n  
B1 76 20 24 12 12 8 0.003 
B2 31 3 7 5 6 10 0.487 
B3 19 1 3 2 8 5 0.058 
B4 15 1 4 5 5 0 0.128 
B5 15 2 6 2 2 3 0.710 
B6 11 0 2 2 4 3 0.391 
B7 8 - - 3 2 3 0.214 
B8 6 - 1 - - 5 0.0004 
B9 5 1 1 3 - - 0.191 
B10 5 1 - - - 4 0.017 
B11 5 - 1 4 - - 0.018 
B12 5 - 2 1 1 1 0.867 
B13 5 1 2 1 1 - 0.812 
Outliers 96 17 22 21 16 20 0.880 
Total 302 47 75 61 57 62  
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Cluster B3 
Cluster B3 accounted for 6% (19/302) of isolates (Figure 3.5). B3 isolates showed no 
significant change over time, 2% (1/47) in 2002 to 8% (5/62) in 2006 (p =0.058) (Table 
3.4 and Figure 3.6). This cluster was consistently present from 2002 through 2006. B3 
isolates were present in 5/9 provinces (Table 3.5), but were most common to Gauteng 
(11/19, 58%). Selected isolates from B3 (4/19, 21%) were sequenced. Three isolates 
were ST6688 and were not assigned to a clonal complex on the MLST database. The 
remaining isolate (No. 7441) was ST2437 and belonged to clonal complex ST-35. 
ST6688 and ST2437 differed by 7 alleles. ST6688 isolates had the same PorA (P1.5,2) 
and FetA type (F5-8). ST2437 contained PorA type P1.22-1,14 while a FetA type could 
not be determined. A PCR product was obtained but sequencing did not yield results. 
  
Cluster B4 
Cluster B4 made up 5% (15/302) of all isolates (Figure 3.5). B4 isolates was present 
from 2002 (1/47, 2%) to 2005 (5/57, 9%) with no reported isolates in 2006 (Table 3.4 
and Figure 3.6). There was no significant increase or decrease (p=0.128) over time. 
The isolates were found in 5/9 provinces (Table 3.5) but were most common to 
Gauteng (7/15, 47%). Selected B4 isolates (2/15, 13%) were sequenced (1 randomly 
selected and 1 with existing MLST data). ST6590 belonged to clonal complex ST-
41/44/lineage 3, while ST4243 was not assigned to a clonal complex on the MLST 
database. ST6590 and ST4243 differed by 3 alleles. Both isolates share the same PorA 
(P1.7,9) and FetA (F3-20) type.  
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Cluster B5 
Cluster B5 also made up 5% (15/302) of all isolates (Figure 3.5). The B5 cluster was 
consistently present throughout the 5-year period: 2002 (2/47, 4%) to 2006 (3/62, 5%) 
(Table 3.4 and Figure 3.6), with no significant increase or decrease (p= 0.710) over 
time. B5 isolates were present in 4/9 provinces (Table 3.5), but were most common to 
Western Cape (7/15, 47%). Isolates selected for sequencing (2/15, 13%) belonged to 
clonal complex ST-865. Two STs were identified, ST6687 and ST7195, and differed by 
1 allele. ST7195 was a new ST. Both isolates share the same PorA (P1.7-1,1) and FetA 
(F1-6) type. 
 
Cluster B6 
Cluster B6 contained 4% of all isolates (11/302) (Figure 3.5). The cluster appeared in 
2003 (2/75, 3%) and was present till the end of the study period, 2006 (3/62, 5%), no 
significant increase or decrease was noted (p=0.391) (Table 3.4 and Figure 3.6). B6 
isolates were found in 3/9 provinces (Table 3.5), and were equally present in 
Gauteng (5/11, 45%) and the Western Cape (5/11, 45%).  
 
Clusters B7-B13  
Clusters B7 to B13 each contained <10 isolates (Figure 3.5). Clusters B8, B10 and B11 
increased from 2002 through 2006 (Table 3.4). Isolates from these seven clusters were 
found in 2 to 4 of the 9 provinces (Table 3.5) but were mostly found in Gauteng and 
the Western Cape. Selected isolates from B7 (1/8, 13%) and B8 (2/6, 33%) analysed 
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and belonged to clonal complex ST-41/44/lineage 3. ST43 identified in cluster B7 
contained PorA type P1.19,15-1 and FetA type F1-5. Isolates from cluster B8 were 
classified as ST6590 (n=2) and had the same PorA (P1.7,9) and FetA (F3-20) type. 
Selected isolates from clusters B10 (1/5, 20%) and B12 (1/5, 20%) belonged to ST-269 
and ST-334 clonal complexes respectively. ST283 identified in cluster B10 contained 
PorA type P1.19-1,30-2 and FetA type F5-1. ST7978 (a new ST) identified in cluster 
B12 contained PorA type P1.12-1,16-8 and FetA type F5-2. 
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Figure 3.6 Meningococcal serogroup B PFGE clusters in South Africa, by year, 2002-2006 (n=302). 
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Table 3.5 Distribution of PFGE clusters causing invasive serogroup B meningococcal disease in South Africa, by province, 2002-2006 
(n=302). 
 
 
Province PFGE clusters Outliers Total 
B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 B11 B12 B13    n (%) 
Western Cape  58 8 5 5 7 5 3 – – 2 2 3 2 39 143  (47) 
Gauteng  13 18 11 7 3 5 2 1 3 3 2 – 2 33 103 (34) 
Eastern Cape  3 – 1 – 2 – – – – – – – – 8 14 (5) 
KwaZulu-Natal  – – – – – – – – – – – 1 – 3 4 (1) 
Mpumalamga – 3 1 – – – 2 – – – – – – 2 8 (3) 
North West  2 2 – 1 – – – – 1 – – – – 2 8 (3) 
Free State  – – 1 – 3 1 – 1 – – – 1 1 6 14 (5) 
Limpopo  – – – 1 – – 1 – – – 1 – – – 3 (1) 
Northern Cape  – – – 1 – – – – 1 – – – – 3 5 (2) 
Total 76 31 19 15 15 11 8 6 5 5 5 5 5 96 302 
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Outliers 
Almost a third of the isolates (96/302, 32%) did not meet the cluster definition 
(Figure 3.5). There were 96 distinct fingerprint patterns among outliers. These 
isolates were found across the country throughout the 5-year period (Figure 3.6 
and Table 3.5). There was no significant change in outliers (p= 0.880), from 2002 
(17/47, 36%) through 2006 (20/62, 32%) (Table 3.4). Selected isolates (11/96, 11%) 
were analysed by MLST, PorA and FetA typing. Results were obtained for 10/11 
(91%) isolates. A total of 10 STs were identified among these outliers, of which 
8/10 (80%) were not assigned to a clonal complex on the MLST database (Table 
3.6). Five new STs were identified. Seven PorA types were identified: P1.21-7,16 
(n=1), P1.17,16-4 (n=2), P1.19,15 (n=1), P1.7,9 (n=1),P1.5,2 (n=3), P1.5-1,2-2 (n=1) 
and P1.5-3,10-24 (n=1). Seven FetA types were identified: F3-16 (n=1), F3-20 (n=1), 
F3-27 (n=1), F4-1 (n=1), F5-34 (n=1), F5-5 (n=3), and F5-8 (n=2). One isolate (9127) 
could not be sequenced by MLST or FetA typing but had a PorA type (P1.22,23-1). 
This isolate did not yield a PCR product for 4/7 MLST genes. A very weak FetA 
PCR product was obtained which sequenced poorly. 
 
Table 3.6 MLST clonal complexes and STs among meningococcal serogroup B 
PFGE outliers, South Africa, 2002-2006. 
NOTE: New STs in bold. 
 
MLST complex 
 
n  
 
STs identified 
no complex 
 
8 
 
ST7392, ST7223, ST3982, ST7946, ST7222, 
ST4240, ST6990, ST6992 
 ST-41/44/lineage 3 
 
1 
 
ST7945 
 
ST-1157  
 
1 
 
ST1157 
Total 10  
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3.2.2 eBURST analysis 
 
The eBURST algorithm divided the isolates (based on STs) into 6 groups (n=23) and 
10 singletons (Table 3.7). The default setting of 6/7 identical loci for the group 
definition was used. A population snapshot was used for representation of all groups 
(Figure 3.7). The diagram was edited to show possible relation of singletons. 
 
Figure 3.7 A population snapshot of N. meningitidis serogroup B isolates, South 
Africa, 2002-2006 (n=33). 
 
 
 
NOTE: Pink lines connect SLV. Blue lines connect DLV. Size of the circle is  
proportional to the number of isolates. 
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Table 3.7 eBURST analysis groups of meningococcal serogroup B isolates, South 
Africa, 2002-2006 (n=23).  
 
NOTE: ST, sequence type. Allele differences indicated in bold. The number of isolates belonging to 
each ST, if more than one, are indicated in parentheses.   
 
3.2.3 PorA types 
A PorA type was obtained for all isolates (n=34). There were 15 PorA types among 
the 34 isolates (Figure 3.8) (Appendix E). Half of all isolates (19/34, 56%) were 
serosubtyped as one of four different PorA types (Table 3.8). PorA type P1.5,2 (6/34, 
18%) was exclusively associated with isolates that were not assigned to a clonal 
complex (6/6). Serosubtypes P1.19,15 (4/34, 12%) and P1.7,9 (5/34, 15%) were most 
associated with clonal complexes ST-32/ET-5 (3/4) and ST-41/44/lineage 3 (4/5).  
Group n ST (n) Alleles 
    
abc adk aroE fumC gdh pdhC pgm 
1 4 154 (2) 3 6 9 5 11 6 9 
  6698 3 3 9 5 11 6 9 
  41 3 6 9 5 9 6 9 
2 5 6688 (3) 15 5 18 24 8 19 62 
  6690 15 5 18 18 8 19 62 
  4240 15 5 9 24 8 19 62 
3 6 33 (5) 8 10 5 4 6 3 8 
  6589 8 10 5 264 6 3 8 
4 4 6590 (3) 9 6 351 9 9 6 311 
  7945 9 6 351 9 26 6 311 
5 2 3982 46 11 79 129 323 9 3 
  7946 46 11 79 129 6 9 3 
6 2 7195 8 5 15 53 8 21 2 
  6687 8 5 15 8 8 21 2 
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Table 3.8 Most common PorA types and associated MLST complexes of N. 
meningitidis serogroup B isolates, South Africa, 2002-2006. 
 
Clonal complex (n) PorA types 
 P1.5,2 P1.19,15 P1.7,9 P1.7-2,4 
ST-32/ET-5 (6)  3   
ST-41/44/lineage 3 (9) 
complex 
  4 4 
no complex (12) 6 1 1  
Total 6 4 5 4 
 
3.2.4 FetA types 
FetA types were obtained for 94% (32/34) isolates (Appendix E). Isolates for which a 
result was not obtained included isolate 9127 (an outlier on PFGE with no MLST 
result) and 7441 (from PFGE cluster B3, belonging to the ST-35 complex). There were 
12 FetA types among the 32 isolates (Figure 3.9). The majority of isolates (21/32, 66%) 
contained one of four FetA (Table 3.9). F5-1 (6/32, 19%) was most associated with ST-
32/ET-5 (5/6). F1-5 (5/32, 16%) and F3-20 (5/32, 16%) were most associated with ST-
41/44/lineage 3. F5-8 (5/32, 16%) was exclusively associated with isolates that were 
not assigned to a clonal complex. Overall, variants of FetA family 5 were most 
common. 
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Table 3.9 Most common FetA types and associated MLST complexes of N. 
meningitidis serogroup B isolates, South Africa, 2002-2006. 
 
 
 
 
Clonal complex FetA types 
 F5-1 F1-5 
 
F5-8 
 
F3-20 
 ST-32/ET-5 (6) 5    
ST-41/44/lineage 3 (9) 
(9)com 
 5  4 
no complex (12)   5 1 
ST-269 (1) 1    
Total 6 5 5 5 
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Figure 3.8 PorA types of N. meningitidis serogroup B isolates in South Africa, 2002-2006 (n=34). 
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Figure 3.9 FetA types of N. meningitidis serogroup B isolates in South Africa, 2002-2006 (n=32). 
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3.2.5 Genotypes  
 
Isolates were assigned an MLST, PorA and FetA genotype. A genotype was 
determined for 32/34, (94%) (Figure 3.10). The majority of isolates belonged to clonal 
complexes ST-32/ET-5 (6/34, 18%), ST-41/44/lineage 3 (9/34, 26%) and isolates not 
assigned to a clonal complex (12/34, 35%). A total of 14 genotypes were found, ST-
32/ET-5 (3/14), ST-41/44/lineage 3 (3/14) and isolates not assigned to a clonal 
complex (8/14) (Figure 3.10). The most common genotype overall was P1.5,2:F5-8:no 
complex (n=5). Common genotypes in the ST-32/ET-5 complex included P1.19,15:F5-
1: ST-32/ET-5 (n=2) and P1.12-1,13-1:F5-1: ST-32/ET-5 (n=3). Genotypes P1.7,9:F3-
20:ST-41/44/lineage 3 (n=4) and P1.7-2,4:F1-5: ST-41/44/lineage 3 (n=4) were equally 
common. The remaining genotypes were each represented by 1 isolate.  
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Figure 3.10 Genotypes of N. meningitidis serogroup B isolates, South Africa, 2002-
2006. 
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3.3 Molecular characterisation of N. meningitidis serogroup B isolates, 2005  
 
A total of 58 N. meningitidis isolates were identified as serogroup B in 2005. Of 
these, 57 were fully characterised by PFGE, MLST, PorA and FetA typing. One 
isolate was non-viable. Isolates were processed by MLST, PorA and FetA typing as 
part of a separate study.  
 
3.3.1 PFGE 
 
Using the cluster definition 49% (28/57) of isolates were divided into 3 clusters, 
B05-1, B05-2 and B05-3 while 51% (29/57) were outliers (Figure 3.11). A total of 54 
fingerprint patterns were generated. Overall 93% (53/57) of isolates shared a >60% 
similarity by PFGE.   
 
Cluster B05-1 
The largest cluster, B05-1, contained 21% (12/57) of all isolates (Figure 3.11). B05-1 
isolates were distributed among 3 provinces (Figure 3.12), but was most common 
to the Western Cape Province (9/12, 75%). All isolates belonged to clonal complex 
ST-32/ET-5 (Table 3.11). Seven STs were identified, ST33, ST2400, ST639, ST484, 
ST6386, including 2 new STs ST6589 and ST6700. The most common ST was ST33 
(5/12). Four serosubtypes and 3 FetA type were found in this cluster, P1.19.15 
(5/12) and F5-1 (9/12) were the most common. ST-32/ET-5:P1.19.15:F5-1 was the 
most common genotype among the six genotypes identified (Table 3.10).  
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Cluster B05-2 
Cluster B05-1 contained 18% (10/57) of all isolates (Figure 3.11). Isolates were 
distributed among 4 provinces (Figure 3.12), but was most common to Gauteng 
Province (7/10, 70%). None of the isolates were assigned to a clonal complex 
(Table 3.11). Five STs were identified, ST4240 and new STs ST6690, ST6692, 
ST6699 and ST6688, the most common being ST6688 (5/10). The cluster was 
dominated by one serosubtype and one FetA type, P1.5,2 and F5-8 respectively. 
Therefore clusterB05-2 contained one genotype, no complex:P1.5,2:F5-8 (Table 
3.10). 
 
Cluster B05-3 
Cluster B05-3 made up 11% (6/57) of all isolates (Figure 3.11). Isolates were 
distributed between 2 provinces (Figure 3.12), but was most common to Gauteng 
Province (5/6, 83%). All isolates belonged to clonal complex ST-41/44/lineage 3 
(Table 3.11). Five STs were identified, ST154 and ST1960 and new STs, ST6694, 
ST6697 and ST6698. The most common ST was ST154 (2/6). Two serosubtypes, 
P1.7-2,4 (5/6) and P1.7-2,13-1 (1/6) and 1 FetA type, F1-5, were found in this 
cluster. ST-41/44/lineage 3:P1.7-2,4:F1-5 was the most common genotype (Table 
3.10). 
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Figure 3.11 PFGE dendrogram with MLST, PorA and FetA type representing the genetic relationship among serogroup 
B meningococci causing invasive disease in South Africa, 2005 (n=57). 
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ST-41/44/lineage 3 comp.
ST-41/44/lineage 3 comp.
ST-41/44/lineage 3 comp.
no complex
ST-41/44/lineage 3 comp.
ST-41/44/lineage 3 comp.
ST-41/44/lineage 3 comp.
P1.5-1,10-1
P1.18-1,3
P1.7-1,1
P1.7-1,1
P1.7-2,4
P1.7-2,4
P1.7-2,4
P1.7-2,4
P1.7-2,4
P1.7-2,13-1
P1.19,15
P1.18-1,34/34-2
P1.5,2
P1.5,2
P1.5,2
P1.5,2
P1.5,2
P1.5,2
P1.5,2
P1.5,2
P1.5,2
P1.5,2
P1.22-1,14
P1.22-1,14
P1.22-1,14
P1.22-1,14
P1.22,13-37
P1.17,16-4
P1.17,16-4
P1.19,15
P1.19,15
P1.12-1,13-1
P1.19,15
P1.12-1,13
P1.5,2-1
P1.12-1,13
P1.19,15
P1.12-1,13-1
P1.12-1,13-1
P1.19,15
P1.19,15
P1.21-7,16
P1.18-1,3
P1.19,15
P1.5,2
P1.7,9
P1.5-2,10-1
P1.17,16-4
P1.7,9
P1.7,9
P1.19,15
P1.7,9
P1.7,9
P1.22,26
P1.7,9
P1.18,25/25-7
P1.7,9
F1-7
F3-9
F1-6
F1-6
F1-5
F1-5
F1-5
F1-5
F1-5
F1-5
F1-5
F5-2
F5-8
F5-8
F5-8
F5-8
F5-8
F5-8
F5-8
F5-8
F5-8
F5-8
ND
F3-7
ND
ND
F4-1
F5-5
F4-1
F5-1
F5-1
F5-1
F5-1
F5-1
F5-18
F3-7
F3-7
F5-1
F5-1
F5-1
F5-1
F5-5
F1-99
F3-16
F3-16
F1-20
F1-5
F4-23
F3-20
F5-1
F3-20
F3-20
F3-20
F3-20
F3-20
F3-9
F3-20
 
 
NOTE : * Province - EC, Eastern Cape; FS, Free State; GA, Gauteng; KZ, KwaZulu-Natal; LP, Limpopo; MP, Mpumalanga; NC, Northern Cape; NW, North West; WC, Western Cape.  
ST, sequence type. cc, clonal complex. ND, Not determined. # denotes isolates that were part of the random selection. 
Isolate     *    Year    ST          cc                PorA           FetA 
   no. 
B05-1 
n=12 
B05-2 
n=10 
B05-3 
n=6 
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Outliers 
Half of the 2005 serogroup B isolates were outliers (29/57, 51%) (Figure 3.11). They 
were distributed among 6 provinces (Figure 3.12) but were most common to the 
Western Cape (14/29, 48%) and Gauteng (10/29, 34%) provinces. The isolates fell into 
different clonal complexes (Table 3.11), the majority (11/29) belonged to ST-
41/44/lineage 3. A total of 26 STs were identified, all of which were represented by a 
single isolate except ST35 (n=3) and ST6590 (n=2). Most of the STs were new (18/26). 
There were 14 PorA types sand 14 FetA types among outliers and 21 PorA:FetA 
combinations. 
 
Figure 3.12 Provincial distribution of N. meningitidis serogroup B PFGE clusters, 
South Africa, 2005 (n=57). 
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Table 3.10 Genotypes of N. meningitidis serogroup B isolates by PFGE clusters 
(n=28), South Africa, 2005. 
 
Cluster Genotypes 
 n Clonal complex PorA FetA n 
B05-1 12 ST-32/ET-5 P1.19,15 F5-1 5 
   P1.12-1,13-1 F5-1 3 
   P1.12-1,13 F5-1 1 
   P1.5,2-1 F5-18 1 
   P1.12-1,13 F3-7 1 
   P1.19,15 F3-7 1 
B05-2 10 no complex P1.5,2 F5-8 10 
B05-3 6 ST-41/44/lineage 3 P1.7-2,4 F1-5 5 
   P1.7-2,13-1 F1-5 1 
 
 
Table 3.11 MLST clonal complexes of N. meningitidis serogroup B isolates, South 
Africa, 2005 (n=57). 
 
Clonal complex B05-1 B05-2 B05-3 Outliers 
ST-32/ET-5 12    
no complex  10  6 
ST-41/44/lineage 3   6 11 
ST-35 complex    5 
ST-334 complex    2 
ST-865 complex    2 
ST-103 complex    1 
ST-1157 complex    1 
ST-269 complex    1 
Total 12 10 6 29 
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3.3.2 MLST 
 
Most of the 2005 serogroup B isolates belonged to clonal complexes ST-32/ET-5 
(12/57, 21%) and ST-41/44/lineage 3 (17/57, 30%) (Table 3.11) (Appendix E). Almost 
a third were not assigned to a clonal complex. A total of 43 STs were identified. The 
most common STs were ST33 (n=5), ST6688 (n=5) and ST35 (n=3). ST639, ST154 and 
ST4240 were each represented by 2 isolates while the remaining STs (24/43, 56%) 
were each represented by a single isolate. A total of 44 isolates could be assigned a 
group by eBURST (Table 3.12). A population snapshot (Figure 3.13) using eBURST 
grouped STs from the most important clonal complexes, ST-32/ET-5 and ST-
41/44/lineage 3, as well as isolates not assigned to a complex. Predicted primary 
founders included ST33, ST154, ST6590 and ST6688. 
 
Singletons 
There were 13 singletons (Figure 3.13). The diagram was manually edited to show the 
relationship of singletons to other STs. Seven singletons were shown to be DLVs of 
other STs. ST1157, ST393 and ST1878 belonged to clonal complexes ST-1157, ST-269 
and ST-103 respectively and were each represented by a single isolate. ST6993 and 
ST6991 were not assigned to a clonal complex. ST6993 is a TLV of primary founder 
ST6950 but ST6991 was not a variant of any ST within the population. ST1960 belongs 
to ST41/44/lineage 3 but is a triple locus variant (TLV) of primary founder ST154.  
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Table 3.12  eBURST analysis groups of meningococcal serogroup B isolates (n=44), 
South Africa, 2005 
 
NOTE: ST, sequence type. Allele differences indicated in bold. The number of isolates belonging to 
each ST, if more than one, are indicated in parentheses. Underlined STs are predicted primary 
founders. 
Group ST (n) Alleles 
 n  abc adk aroE fumC gdh pdhC pgm 
1 12 33 (5) 8 10 5 4 6 3 8 
  639 (2) 8 10 5 9 6 3 8 
  484 8 10 5 4 9 3 8 
  6589 8 10 5 264 6 3 8 
  6368 8 35 5 4 6 3 8 
  2400 8 5 5 4 6 3 8 
  6700 8 10 5 9 9 3 8 
2 11 6688 (5) 15 5 18 24 8 19 62 
  4240 (2) 15 5 9 24 8 19 62 
  6692 15 5 18 9 8 19 62 
  6690 15 5 18 18 8 19 62 
  6990 15 5 9 9 8 19 62 
  6699  12 5 18 24 8 19 62 
3 6 6590 (2) 9 6 351 9 9 6 311 
  6701 9 6 351 9 9 6 3 
  6695 9 6 351 9 9 6 17 
  6710 9 6 483 9 9 6 311 
  6989 9 6 351 24 9 6 311 
4 5 154 (2) 3 6 9 5 11 6 9 
  6697 3 6 9 24 11 6 9 
  6694 3 6 9 4 11 6 9 
  6698 3 3 9 5 11 6 9 
5 2 865 8 5 15 17 8 21 2 
  6687 8 5 15 8 8 21 2 
6 2 6992 47 3 482 4 21 59 49 
  6709 47 3 482 76 21 59 49 
7 2 334 14 5 6 9 3 8 18 
  6704 14 5 6 76 3 8 18 
8 4 35 (3) 4 10 11 18 6 10 12 
  6703 47 10 11 18 6 10 12 
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Figure 3.13 A population snapshot of N. meningitidis serogroup B isolates, South 
Africa, 2005 (n=57). 
 
 
NOTE: Size of circle is proportionate to the number of isolates included in the analysis. Blue 
circles depict the predicted primary founder. Pale blue lines join single-locus variants.  
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3.3.3 PorA  
 
A serosubtype was obtained for all 57 isolates (Figure 3.14). There were 19 PorA 
types. Almost half of all isolates (32/57, 56%) contained 1 of 3 PorA types (Table 
3.13), P1.5,2 (n=11), P1.19,15 (n=9) and P17,9 (n=7). 
 
Table 3.13 Most common N. meningitidis sergroup B PorA types and associated 
MLST complexes, South Africa, 2005.  
 
3.3.4 FetA 
 
FetA types were obtained for 54/57 isolates processed (Figure 3.15). The 3 isolates for 
which a FetA type could not be determined belonged to clonal complex ST-35 and 
were of the following STs, ST35, and new STs, ST6703 and ST6693. There were 16 
FetA types among the 2005 serogroup B isolates. The majority of isolates (35/54, 65%) 
contained 1 of 4 FetA types (Table 3.14). 
 
 
 
Clonal complex (n) PorA types 
 P1.5,2 P1.19,15 P1.7,9 P1.7-2,4 
no complex (16) 11 1 1  
ST-32/ET-5 (12)  6   
ST-41/44/lineage 3 (17) 
complex 
 2 6 5 
Total 11 9 7 5 
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Table 3.14 Most common N. meningitidis sergroup B FetA types and associated 
MLST complexes, South Africa, 2005. 
 
 
Clonal complex (n) FetA types 
 F5-1 F5-8 F1-5 F3-20 
no complex  (16)  10  1 
ST-32/ET-5 (12) 9    
ST-41/44/lineage 3 (17) 1  1 6 
ST-334 (2)   7  
Total 10 10 8 7 
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   Figure 3.14 PorA types of N. meningitidis serogroup B isolates in South Africa, 2005 (n=57). 
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Figure 3.15  FetA types of N. meningitidis serogroup B isolates in South Africa, 2005 (n=57). 
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4 DISCUSSION 
 
South Africa has documented meningococcal disease since the early 1900’s [67] and is 
set apart from the rest of Africa in terms of serogroups responsible for invasive cases. 
Serogroup B causes 60-80% of meningococcal disease in countries in North and South 
America, parts of Europe, middle-east Asia, New Zealand and Australia [21;165]. 
However cases of serogroup B are rarely seen in most African countries. 
 
Limited data are available regarding the molecular epidemiology of serogroup B 
meningococci in our country. Coulson et al. [79] described the epidemiology of 
invasive meningococcal disease in South Africa from August 1999 through July 2002 
where serogroup B caused 41% of laboratory-confirmed cases during this period. 
Selected isolates from the three main serogroup B PFGE clusters were analysed by 
MLST, and hyperinvasive clonal complexes ST-32/ET5 and ST-41/44/lineage 3 were 
identified. The current study describes the genotypes of circulating serogroup B 
meningococci over a five-year period in South Africa, from 2002 to 2006. 
 
Meningococcal disease epidemiology in South Africa, 2002-2006 
From January 2002 through December 2006 sporadic cases of meningococcal disease 
occurred throughout each year with seasonal increases in the winter and spring 
months (May to October). The year round occurrence of meningococcal disease, 
including seasonal variation, has been previously described in South Africa [72;79] 
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and the United States [52;55]. Cases occurred across the country but were most 
commonly reported in the Western Cape and Gauteng provinces. Two serogroups, B 
and W135, were predominant, accounting for almost two thirds of cases. These were 
reported from all regions in the country, but were most common to the Western Cape 
and Gauteng provinces respectively. Improved reporting, through the national 
surveillance system, from these metropolitan areas may also have contributed to the 
higher numbers of confirmed cases. There was an overall decrease in serogroup B 
disease over the 5-year period. 
 
Age-specific incidence rates were highest in children less than 5 years of age, for 
overall disease as well as serogroup B disease. Incidence rates were similar to those 
seen in the United States [52], Europe and Ireland [165;175]. Coulson et al. also 
reported the highest incidence in the less than 5-year age group, particularly in 
infants less than 1 year of age. With regard to gender, slightly more than half of 
invasive serogroup B cases (55%) occurred in males, however this was not statistically 
significant.  
 
Among those cases wehee the final outcome was known the case-fatality ratio (CFR) 
was 9%. Several studies have reported similar and lower CFRs for serogroup B 
disease outside of epidemics [175-178]. In the United States, a significant association 
has been shown to exist between outbreaks (after adjusting for serogroups)  and 
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increased CFR compared to sporadics cases [179]. Studies have reported higher CFRs 
for serogroups A, C and W135 [81;177;178]  .  
 
Serogroup B characterisation by PFGE and MLST 
Serogroup B PFGE and MLST data from 2005 demonstrated the correlation between 
the two methods and therefore supported inferences made with the larger collection 
of isolates. As expected, PFGE showed substantial diversity among invasive isolates 
which is charactersistic of serogroup B globally [52;60], especially in countries where 
disease is mostly sporadic. Compared with serogroups A, C, Y and W135 which tend 
to be more clonal [80;126;128], serogroup B strains causing sporadic disease are 
generally more diverse. Serogroup B meningococci isolated in South Africa from a 
previous study also demonstrated high levels of diversity [79]. This diversity is 
attributed to high rates of recombination and phase variation within the naturally 
transformable meningococcal population [157;162]. Despite this diversity, the 
majority of isolates collected over the 5-year period could be grouped into several 
clonal clusters. 
 
Overall, the most predominant clone in South Africa was clonal complex ST-32/ET-5. 
From August 1999 through July 2002, the ST-32/ET-5 clone was responsible for 37% 
(90/245)of serogroup B disease [79]. However, of the serogroup B isolates analysed 
for this study, ST-32/ET-5 caused approximately 25% of cases, indicating a decline in 
the prevalence of this clone. This clonal complex was found circulating mostly in the 
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Western Cape with a significant decrease over the five-year period. ST-32/ET-5 
strains are considered hyperinvasive and have spread between continents since the 
1970s causing outbreaks of varying magnitudes [169;170]. In this study, eBURST 
showed that ST33 was the primary founder of ST-32/ET-5 strains. ST33 is a SLV of 
ST32 and a subgroup founder within the ST-32/ET-5 complex [180]. A substantial 
amount of invasive meningococcal disease in Europe is due to ST-32/ET-5 [37;56;181] 
however proportions of cases due to this clone differ greatly between European 
countries [182]. 
 
Norway experienced an epidemic caused by a single ST-32/ET-5 clone [59;166] which 
spanned at least 20 years (1970s-1990s) [66]. In the United States the state of Oregon 
continues to experience an outbreak, which began in 1993 [52;64], caused by ST-
32/ET-5 strains. Excluding isolates from Oregon, approximately one third of invasive 
serogroup B isolates collected in the USA through the ABC Surveillance system, from 
2000 through 2005, belonged to clonal complex ST-32/ET-5 [55]. In 1983, Cuba 
experienced a peak in incidence of their meningococcal epidemic [63]. The 
predominant clone was ST-32/ET-5, the same clone that caused an increase in disease 
incidence in Sao Paulo, Brazil [38;57;58]. This clone also caused an outbreak in the city 
of Iquique, Chile in the 1980s [62;183]. In addition, Japan and Taiwan have also 
reported disease caused by ST-32/ET-5 strains [61;122]. 
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The second most predominant clonal complex in South Africa was ST-41/44/lineage 
3. From August 1999 through July 2002, the ST-41/44/lineage 3 clone was responsible 
for 9% (22/245)of serogroup B disease and was also the second most predominant 
complex [79].Unlike ST-32/ET-5, the ST-41/44/lineage 3 clonal complex was found 
mostly in Gauteng, where it was previously identified by Coulson et al. [79]. Strains 
of the ST-41/44/lineage 3 complex are highly diverse [182]. It is the only complex for 
which two central STs have been defined. ST41 is largely associated with invasive 
disease while ST44 tends to be associated with meningococcal carriage [184]. In this 
study, eBURST identified ST154 and ST6590 as primary founders of ST-41/44/lineage 
3 strains. ST154 is a SLV of ST41 and a subgroup founder within the clonal complex 
[180]. ST110 is a SLV of ST44 and a subgroup founder within the ST-41/44/lineage 3 
complex. ST6590 is a DLV of ST110. Strains of the ST-41/44/lineage 3 clonal complex 
have been shown to cause substantial disease in Europe [37;56], Japan [61] and 
Taiwan [122],  more so than ST-32/ET-5.  
 
ST-41/44/lineage 3 strains emerged in the 1980s in the Netherlands [167]. During this 
time the Netherlands experienced an increase in meningococcal disease incidence, 
mostly caused by this clone [53;59]. In New Zealand, ST-41/44/lineage 3 strains were 
responsible for a 10-year epidemic [65]. ST154 was responsible for a substantial 
amount of disease during this time. The epidemic began in mid-1991, reached peak 
incidence in 2001 (17.4 cases/100 000 population) and subsequently began to wane 
[185].  
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A substantial proportion of invasive isolates in this study belonged to STs that were 
not assigned to a known clonal complex. Some STs were related to each other. 
Among these STs eBURST predicated the primary founder to be ST6688. The majority 
of these ST’s were new and appear to be unique to South Africa at this time. 
Unassigned STs have been reported in the USA [186], Europe [37;56] and elsewhere 
[58;61;110;122]. Other important clonal complexes that were identified included ST-
269, ST-35, ST-334 and ST-103. Clonal complex ST-269 has expanded in Europe and is 
responsible for a substantial portion of invasive disease [37;56;187;188]. There have 
been reports of an increase in ST-269 following the introduction of the meningococcal 
C vaccine in Canada [189] and Scotland [188] with suggestions of possible capsule 
switching (between C and B) in Canada. ST-269 strains have also been identified in 
the USA [186], Cuba [110] and Europe [182].  
 
ST-35 made up approximately 4% of serogroup B isolates. From August 1999 through 
July 2002 Coulson et al. [79] identified the ST-35 clone as the third most predominant 
complex (15/245, 6%) preceded only by clones ST-32/ET-5 and ST-41/44/lineage 3. 
ST-35 strains have been described in the USA and Europe [182;186]. Two ST-35 
isolates (ST35 and ST2437) did not fall into the same PFGE cluster as other ST-35 
strains. PFGE was repeated on these isolates to ensure that the fingerprint patterns 
were correct, and the same result was obtained. ST35 was an outlier while ST2437 (a 
SLV of the ancestral ST35) was closely related to strains that were not assigned to a 
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clonal complex. It is possible that recombination events led to substantial changes in 
the genome resulting in related STs having different PFGE fingerprint patterns.  
 
ST-334 strains have been described in the USA [186]. Clonal complex ST-103 was 
represented by one isolate (ST1878, among outliers) identified as a SLV of the 
ancestral ST (ST103). ST-103 strains have been described in Cuba [110], the USA [186] 
and Brazil [58]. Identification of serogroup B isolates belonging to these clonal 
complexes indicates possible capsule switching from serogroup C to B since strains of 
ST-334 and ST-103 are mostly associated with serogroup C [186] according to the 
central MLST database. 
 
ST-865 comprised approximately 5% of all serogroup B isolates in this study. Coulson 
et al. [79] identified serogroup C ST-865 strains (9/49, 18%) in South Africa. At the 
time ST-865 was the second most predominant complex among serogroup C isolates 
preceded by the ST-11/ET-37 clone (13/49, 27%) A recent study in our unit 
(unpublished data) showed that ST-865 has expanded, as the majority of serogroup C 
isolates from 2005 belonged to ST-865. Capsule switching among ST-865 strains was 
indicated by serogroup C isolates from 2005 having the same genotype, P1.7-1,1:F1-
6:ST865, as a serogroup B strain isolated in the same year. It is not always possible to 
determine the direction of caspular switching, however, since ST-865 is usually 
associated with serogroup B (according to the central MLST database), it is possible 
that the direction of the switch was from serogroup
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For other organisms eg. Streptococcus pneumoniae, capsular switching following 
routine vaccine implementation, has been demonstrated [190;191]. Recently, Harrison 
et al. [186] reported that capsular switching, especially amongst serogroup B, C and Y 
meningococcal isolates, was evident among USA invasive isolates prior to the 
introduction of the meningococcal C conjugate vaccine (MCV4). The study confirmed 
that capsular switching can occur as a natural occurrence in the absence of vaccine or 
other selective pressures. [186;192-194]. To date, capsular switching has not been 
identified in the United Kingdom where routine MCV4 vaccination has been 
implemented [195]. The SA strains exhibited capsular switching in the absence of any 
vaccine pressure. A potential switch between sergroup Y and B has been reported in 
Canada [196]. While ST-865 strains were not identified among serogroup B and C 
isolates in the USA [186], they were reported among serogroup B isolates in Taiwan 
[122].  
 
PorA  types 
As expected, there was substantial PorA diversity among the isolates. The most 
common PorA types during the 5-year period included P1.5,2; P1.19,15; P1.7,9 and 
P1.7-2,4 These serosubtypes have been identified elsewhere [110;186;197-201]. 
P1.19,15 was associated with high disease incidence in Cuban, Brazil and Spain. 
Based on data from the central MLST database, P1.19,15 was the dominant PorA type 
of the ST-32/ET-5 clonal complex [165]. P1.7-2,4 is associated with the clone 
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responsible for the New Zealand epidemic. Devoy et al. [202] showed that this PorA 
type was relatively stable throughout the epidemic and therefore could be used in an 
OMP-based vaccine [202]. Based on data from the central MLST database P1.7-2,4 is 
the dominant PorA type of the ST-41/44/lineage 3 clonal complex [165]. Previous 
studies using meningococci from South African complement-sufficient and 
complement-deficient individuals determined PorA type, however monoclonal 
antibodies were used and determined either VR1 or VR2 [172;203]. Therefore it was 
difficult to compare findings. Multiple mechanisms of phase variation, which lead to 
a high degree of diversity, have been described for PorA [204]. Deletion of PorA has 
been reported to occur via recombination involving palindromic RS3 core sequences 
[205]. However, PorA-deficient isolates have been reported to cause invasive disease 
[206]. 
 
FetA types 
Isolates were also quite diverse by FetA. The most common FetA types were F5-1, F5-
8, F1-5 and F3-20. These FetA types have been identified globally [110;147;186;207]. In 
this study, F5-1 and F1-5 were the dominant types of the ST-32/ET-5 and ST-
41/44/lineage 3 clonal complexes, respectively. The FetA type of four isolates could 
not be determined. Repeated attempts failed to produce PCR products fro three of the 
four isolates. The fourth isolate produced a PCR product that was slightly smaller 
than the expected band size. Very poor sequencing results were obtained for this 
product. No further work was done on these isolates. These isolates belonged to 
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different STs of the ST-35 clonal complex but had the same PorA type. FetA gene 
deletions have been reported in different clones but mostly among isolates of the ST-
35 complex and have been found in both invasive and carriage isolates [155;208]. 
Marsh et al. [208] attributed the deletions to genetic recombination of RS3 repetitive 
elements, similar to PorA deletions, while Claus et al. [155] showed that, in addition 
to RS3 recombination, different mechanisms of intragenomic recombination and 
rearrangement were responsible for the fetA deletions. PorA in three of the isolates 
was the same type as those FetA deficient isolates reported from the USA [208] and 
Germany [155]. 
 
Genotypes 
Common genotypes included P1.5,2:F5-8:no complex; P1.19,15:F5-1:ST-32/ET-5; P1.7-
2,4:F1-5:ST-41/44/lineage 3 and P1.7,9:F3-20:ST-41/44/lineage 3. P1.5,2:F5-8:no 
complex has been reported in Germany but among serogroup C isolates [207]. 
P1.19,15:F5-1:ST-32/ET-5 was frequently identified in Cuba [110]. P1.7-2,4:F1-5:ST-
41/44/lineage 3 was prevalent among German [207] and USA [186] isolates. Urwin et 
al. [147] used a global collection of isolates representative of hyperinvasive lineages to 
examine the antigenic diversity of PorA, FetA and PorB among meningococci. The 
study identified the P1.7-2,4:F1-5 combination as the most common among ST-
41/44/lineage 3 strains [147]. The genotype causing the ongoing epidemic in Oregon, 
USA (P1.7,16:F3-3:ST-32/ET-5) [186] was not identified among the South African 
isolates.  
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5 CONCLUSIONS 
 
Serogroup B molecular epidemiology in South Africa from 2002 through 2006 is 
similar to that described globally, for sporadic disease. The isolates displayed a high 
level of diversity. Over the study period South Africa had a predominance of the two 
most important hyperinvasive serogroup B clonal complexes, ST-32/ET-5 and ST-
41/44/lineage 3. ST-32/ET-5 strains have decreased over time while ST-
41/44/lineage 3 complex strains increased since they were first reported between 
1999 and 2002 [79]. In addition, other clones, ST-269, ST-35, ST-334, ST-103 and ST865, 
were identified. ST-269 has recently expanded in parts of Europe [187] and in Canada 
[189]. Studying the characteristics and structure of meningococcal populations, is 
therefore important for monitoring shifts in meningococcal disease epidemiology.  
 
PFGE and MLST are both valuable techniques for characterisation and should be 
used in conjunction depending on the epidemiological circumstances. PFGE, while 
technically subjective and laborious, has a higher discriminatory power where MLST 
may characterise isolates as the same ST [143]. A combination of DNA-based typing 
schemes is more useful. This would provide further resolution between isolates as 
well as unambiguous data. While capsule switching occurs naturally within the 
meningococcal population [186] the use of vaccines against serogroups A, C, Y and 
W135 may act as a selective pressure under which isolates may switch to other 
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serogroups. Capsule switching in this study was identified in the absence of any 
vaccine pressure. 
   
In the absence of an effective vaccine against serogroup B, widespread group B 
outbreaks may result in substantial morbidity and mortality. The use of strain-
specific OMP vaccines based on PorA type have been successful in controlling 
outbreaks in Chile, Cuba, The Netherlands and New Zealand. However, since the 
vaccines target strains responsible for the outbreaks, they are therefore limited to 
geographic region. Isolates that cause endemic disease are more diverse. South 
African isolates displayed a level of diversity that would require a multivalent 
vaccine of at least four PorA types and four FetA types to prevent at least 50% of 
invasive disease. In addition, deletions of PorA and FetA gene sequences may limit 
the use of these OMPs as vaccine targets because isolates may benefit from these 
deletions under vaccine pressure. A more conserved protein, such as fHBP [209], may 
be more suitable as a vaccine target, affording more comprehensive control of 
meningococcal disease. 
 
N. meningitidis clones have traversed the globe [170]. Continued molecular 
surveillance using multiple typing methods is therefore crucial for monitoring out-
break-associated and emerging clones. Mapping the disease epidemiology within a 
region will assist in public health control strategies by providing data for vaccine 
development and implementation. 
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6 APPENDICES 
 
Appendix A 
 
 
1.  Sentinel sites (dots) across the 9 provinces participate in an  
active enhanced surveillance program.  
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2. Case report form   
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3. Laboratory sterile site isolate form 
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Appendix B 
 
 
1. 1 M Tris-HCL 
- 121.1 g Tris  (Sigma Aldrich, Steinheim, Germany) 
- 800 ml distilled water 
Adjust pH to 8.0 by adding conc. HCL. Adjust volume to 1 L and autoclave. 
 
2. 0.5 M EDTA  
- 186.1 g EDTA (Merck Chemicals, Gauteng, South Africa) 
- 800 ml distilled water 
 Dissolve completely. Adjust pH to 8.0 with NaOH pellets. 
 Make up to 1 L and autoclave. 
 
3. TE Buffer 
 
- 5 ml 1M Tris-HCL (pH 8.0) 
- 1 ml 0.5M EDTA (pH 8.0) 
- 494 ml distilled water 
Mix and autoclave at 121°C. 
 
 
4. Lysozyme 
 
- 10 mg lysozyme (Sigma Aldrich, Steinheim, Germany) 
- 1 ml distilled water 
 1 ml stock solutions stored at -20°C. 
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5. Proteinase-K 
- 20 mg proteinase-K  (Roche, Mannheim, Germany) 
- 1 ml distilled water 
 1 ml stock solutions stored at -20°C. 
 
 
6. 5x TBE  
- 54 g Trizma (Sigma-Aldrich, Steinheim, Germany)  
- 27.5 g Boric acid (Sigma-Aldrich, Steinheim, Germany) 
- 4.65 g EDTA (Merck Chemicals, Gauteng, South Africa) 
   Make up to 1 L with deionised water. 
 
7. 0.5x TBE  
- 100 ml 5x TBE buffer 
- 900 ml distilled water 
Mix well. 
 
8. 1.2% Seakem Gold Agarose 
- 0.3 g Seakem Gold Agarose  (Lonza, Rockland, USA) 
- 25 ml 0.5x TBE buffer 
 Dissolve agarose completely by boiling. 
 
9. 10 % SDS  
- 100 g SDS (BDH Lab Supplies, Poole, England) 
- 900 ml distilled water 
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 Heat to 68°C to assist dissolution. Adjust pH to 7.2 by adding conc. HCL 
 Adjust to 1 L. Do not autoclave! 
 
10. Cell Lysis Buffer (25 ml)  
- 25 ml EDTA (0.5 M, pH 8.0) 
- 0.25 g sarkosyl [final = 1 %] (Sigma-Aldrich, Steinheim, Germany) 
- 2.5 mg Proteinase-K [final = 0.1mg/ml] (Roche Diagnostics, Mannheim, 
Germany) 
 Make up fresh. 
 
11. 1x Restriction Buffer 
- 10 µl 10x restriction buffer (Roche Diagnostics , Mannheim, Germany) 
- 90 µl distilled water 
 Make up fresh. 
 
12. NheI Restriction Enzyme Cocktail (100 µl) 
- 0.5 µl of 40 U/µl NheI restriction enzyme (Roche Diagnostics, 
Mannheim, Germany) 
- 10 µl 1x restriction buffer 
- 90 µl distilled water 
 Make up fresh. 
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13. Ethidium Bromide Solution (300 ml) 
- 300 ml 0.5x TBE buffer 
- 30 µl of 10 mg/ml ethidium bromide [final = 1 mg/ml] 
Use twice before discarding.  
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Appendix C 
 
  Appendix D 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix D  
PFGE dendrogram with MLST, PorA and FetA type representing the genetic relationship among serogroup B 
meningococci causing invasive disease in South Africa, 2002-2006 (n=302).  
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NOTE: # denotes randomly selected isolates. ST, sequence type. cc, clonal complex. ND, not determined 
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Appendix E 
 
N. meningitidis serogroup B isolates sequenced by MLST, PorA and FetA typing, 2002-2006 (n=85)  
 
Year Lab no. Alleles ST Clonal complex PorA FetA 
    abc adk aroE fumC gdh pdhC pgm   VR1,VR2  
2002 7574 8 10 5 4 6 3 8 33 ST-32/ET-5 P1.19, 15 F3-7 
 6305 9 6 350 9 8 21 311 4243 no complex P1.7, 9 F3-20 
 8257 8 10 5 4 6 3 8 33 ST-32/ET-5 P1.12-1,13-1 F5-1 
 6894 47 3 512 31 8 87 13 7392 no complex P1.5-1,2-2 F3-27 
 7656 8 10 5 4 6 3 8 33 ST-32/ET-5 P1.12-1,13-1 F5-1 
 7419 8 10 5 4 6 3 8 33 ST-32/ET-5 P1.19, 15 F5-1 
2003 9542 14 6 6 76 3 8 18 6704 ST-334 P1.12-1, 16-8 F5-2 
 9203 8 5 15 8 8 21 2 6687 ST-865 P1.7-1, 1 F1-6 
 13072 8 5 15 53 8 21 2 7195 ST-865 P1.7-1, 1 F1-6 
 12691 8 10 5 4 6 3 8 33 ST-32/ET-5 P1.19, 15 F5-1 
 10438 12 2 15 455 58 11 3 7223 no complex P1.17, 16-4 F5-34 
 
9076 9 6 351 9 9 6 311 6590 ST41/44/lineage 3 P1.7, 9 F3-20 
 
12780 8 10 5 264 6 3 8 6589 ST-32/ET-5 P1.12-1,13-1 F5-1 
2004 14149 46 11 79 129 6 9 3 7946 no complex P1.5-3, 10-24 F5-5 
 16186 3 6 9 5 11 6 9 154 ST41/44/lineage 3 P1.7-2, 4 F1-5 
 17653 15 5 9 8 28 19 62 7222 no complex P1.5, 2 F5-8 
 15733 9 6 351 9 26 6 311 7945 ST41/44/lineage 3 P1.7, 9 F3-20 
 13172 46 11 79 129 323 9 3 3982 no complex P1.19, 15 F5-5 
2005 36 8 5 15 8 8 21 2 6687 ST-865 complex P1.7-1,1 F1-6 
 6 8 35 5 4 6 3 8 6368 ST-32/ET5  P1.19,15 F5-1 
 94 4 35 15 9 8 11 9 393 ST-269  P1.5-1,10-1 F1-7 
 302 15 5 18 24 8 19 62 6688 no complex P1.5,2 F5-8 
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Year Lab no. Alleles ST Clonal complex PorA FetA 
    abc adk aroE fumC gdh pdhC pgm   VR1,VR2  
2005 371 4 10 11 18 6 10 12 35 ST-35 complex P1.22,13-37 F4-1 
 372 4 10 11 18 6 10 12 35 ST-35  P1.22-1,14 F3-7 
 430 9 6 351 9 9 3 9 6689 ST-41/44 /lineage 3 P1.7,9 F5-1 
 652 15 5 18 18 8 19 62 6690 no complex P1.5,2 F5-8 
 616 9 6 351 24 9 6 311 6989 ST-41/44 /lineage 3 P1.7,9 F3-20 
 995 8 10 5 9 6 3 8 639 ST-32/ET5 P1.12-1,13-1 F5-1 
 1027 15 5 18 9 8 19 62 6692 no complex P1.5,2 F5-8 
 1228 15 5 9 24 8 19 62 4240 no complex P1.5,2 F5-8 
 1310 14 10 11 9 6 10 12 6693 ST-35 P1.22-1,14 ND 
 1557 3 6 9 4 11 6 9 6694 ST-41/44 /lineage 3 P1.7-2,4 F1-5 
 1835 8 10 5 4 6 3 8 33 ST-32/ET5  P1.12-1,13-1 F5-1 
 1841 8 6 9 17 9 6 9 6696 ST-41/44 /lineage 3 P1.18-1,34/34-2 F5-2 
 1766 15 5 9 24 8 19 62 4240 no complex P1.5,2 F5-8 
 1767 9 6 351 9 9 6 17 6695 ST-41/44 /lineage 3 P1.7,9 F3-20 
 1834 8 10 5 4 9 3 8 484 ST-32 /ET5  P1.19,15 F5-1 
 1936 8 25 7 17 21 26 49 1157 ST-1157  P1.21-7,16 F5-5 
 1937 8 4 6 17 5 8 2 1878 ST-103  P1.18-1,3 F3-9 
 1966 15 5 18 24 8 19 62 6688 no complex P1.5,2 F5-8 
 2093 47 3 482 76 21 59 49 6709 no complex P1.17,16-4 F5-5 
 2136 8 5 5 4 6 3 8 2400 ST-32 /ET5  P1.19,15 F5-1 
 2271 9 6 351 9 9 6 311 6590 ST-41/44 /lineage 3 P1.7,9 F3-20 
 2351 9 6 9 9 9 6 2 180 ST-41/44 /lineage 3 P1.19,15 F1-5 
 2391 4 10 11 18 6 10 12 35 ST-35  P1.22-1,14 ND 
 2439 15 5 18 24 8 19 62 6688 no complex P1.5,2 F5-8 
 2379 3 6 9 24 11 6 9 6697 ST-41/44 /lineage 3 P1.7-2,4 F1-5 
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Year Lab no. Alleles ST Clonal complex PorA FetA 
  abc adk aroE fumC gdh pdhC pgm   VR1,VR2  
2005 2516 8 10 5 4 6 3 8 33 ST-32 /ET5  P1.12-1,13 F3-7 
 2539 3 6 9 5 11 6 9 154 ST-41/44 /lineage 3 P1.7-2,4 F1-5 
 2826 8 5 15 17 8 21 2 865 ST-865  P1.7-1,1 F1-6 
 2640 3 3 9 5 11 6 9 6698 ST-41/44 /lineage 3 P1.7-2,4 F1-5 
 2676 15 5 9 9 8 19 62 6990 no complex P1.5,2 F3-16 
 2718 8 10 5 264 6 3 8 6589 ST-32 /ET5 P1.12-1,13 F5-1 
 2827 9 6 483 9 9 6 311 6710 ST-41/44 /lineage 3 P1.7,9 F3-20 
 2825 15 5 18 24 8 19 62 6688 no complex P1.5,2 F5-8 
 2909 9 6 9 9 8 6 9 1834 ST-41/44 /lineage 3 P1.18,25/25-7 F3-9 
 2953 12 5 18 24 8 19 62 6699 no complex P1.5,2 F5-8 
 3288 3 6 9 5 11 6 9 154 ST-41/44 /lineage 3 P1.7-2,4 F1-5 
 3422 8 10 5 4 6 3 8 33 ST-32 /ET5 P1.19,15 F5-1 
 3395 8 10 5 4 6 3 8 33 ST-32 /ET5  P1.19,15 F5-1 
 3482 9 6 351 9 9 6 311 6590 ST-41/44 /lineage 3 P1.7,9 F3-20 
 3954 8 10 5 9 9 3 8 6700 ST-32 /ET5  P1.19,15 F3-7 
 3952 6 5 2 4 143 16 17 6991 no complex P1.19,15 F3-16 
 3813 3 116 9 5 9 22 9 1960 ST-41/44 /lineage 3 P1.7-2,13-1 F1-5 
 4035 4 3 482 9 21 59 49 6711 no complex P1.7,9 F1-20 
 3950 14 5 6 9 3 8 18 334 ST-334 P1.17,16-4 F4-23 
 3897 15 5 18 24 8 19 62 6688 no complex P1.5,2 F5-8 
 4234 9 6 351 9 9 6 3 6701 ST-41/44 /lineage 3 P1.19,15 F3-20 
 4322 259 6 9 129 9 6 9 6702 ST-41/44 /lineage 3 P1.18-1,3 F1-99 
 4332 47 3 482 4 21 59 49 6992 no complex P1.17,16-4 F4-1 
 4661 8 10 5 9 6 3 8 639 ST-32 /ET5  P1.5,2-1 F5-18 
 4662 41 6 351 76 3 6 311 6993 no complex P1.22,26 F3-20 
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Year Lab no. Alleles ST Clonal complex PorA FetA 
  abc adk aroE fumC gdh pdhC pgm   VR1,VR2  
 4663 8 10 5 4 6 3 8 33 ST-32 /ET5  P1.12-1,13-1 F5-1 
 4660 47 10 11 18 6 10 12 6703 ST-35  P1.22-1,14 ND 
 5102 14 5 6 76 3 8 18 6704 ST-334 P1.5-2,10-1 F1-5 
2006 7637 3 6 9 5 11 6 9 154 ST41/44/lineage 3 P1.7-2, 4 F1-5 
 9127 ND ND ND ND ND ND ND ND ND P1.22,23-1 ND 
 7277 9 6 351 9 9 6 311 6590 ST41/44/lineage  P1.7, 9 F3-20 
 10170 3 3 9 5 11 6 9 6698 ST41/44/lineage 3 P1.7-2, 4 F1-5 
 7466 15 5 9 24 8 19 62 4240 no complex P1.5,2 F5-8 
 5430 3 6 9 5 9 6 9 41 ST41/44/lineage 3 P1.7-2, 4 F1-5 
 8477 4 10 15 9 8 11 17 283 ST269 P1.19-1,30-2 F5-1 
 9800 9 6 351 9 9 6 311 6590 ST41/44/lineage 3 P1.7, 9 F3-20 
 7441 14 10 11 212 6 10 12 2437 ST35 P1.22-1,14 ND 
 10412 15 5 18 24 8 19 62 6688 no complex P1.5,2 F5-8 
 7032 12 6 9 9 9 6 9 43 ST41/44/lineage 3 P1.19,15-1 F1-5 
NOTE : ND, Not determined. ST, sequence type. 
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